<!DOCTYPE article
PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD with MathML3 v1.3 20210610//EN" "JATS-archivearticle1-3-mathml3.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="1.3" xml:lang="en" article-type="review-article"><?properties open_access?><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Small GTPases</journal-id><journal-id journal-id-type="iso-abbrev">Small GTPases</journal-id><journal-title-group><journal-title>Small GTPases</journal-title></journal-title-group><issn pub-type="ppub">2154-1248</issn><issn pub-type="epub">2154-1256</issn><publisher><publisher-name>Taylor &#x00026; Francis</publisher-name></publisher></journal-meta>
<article-meta><article-id pub-id-type="pmid">40396280</article-id><article-id pub-id-type="pmc">PMC12101591</article-id>
<article-id pub-id-type="doi">10.1080/21541248.2025.2505977</article-id><article-id pub-id-type="publisher-id">2505977</article-id><article-version vocab="JAV" vocab-identifier="http://www.niso.org/publications/rp/RP-8-2008.pdf" vocab-term="Version of Record" article-version-type="VoR">Version of Record</article-version><article-categories><subj-group subj-group-type="article-type"><subject>Review Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Review Article</subject></subj-group></article-categories><title-group><article-title>The role of RAC1 in resistance to targeted therapies in cancer</article-title><alt-title alt-title-type="left-running-head">C. URIBE-ALVAREZ AND J. CHERNOFF</alt-title><alt-title alt-title-type="right-running-head">SMALL GTPASES</alt-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Uribe-Alvarez</surname><given-names>Cristina</given-names></name><xref rid="aff0001" ref-type="aff"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/" vocab-term="Conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab-term="Formal analysis">Formal analysis</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab-term="Investigation">Investigation</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/" vocab-term="Writing &#x02013; original draft">Writing &#x02013; original draft</role></contrib><contrib contrib-type="author"><name><surname>Chernoff</surname><given-names>Jonathan</given-names></name><xref rid="aff0001" ref-type="aff"/><xref rid="an0001" ref-type="corresp"/><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/" vocab-term="Conceptualization">Conceptualization</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/funding-acquisition/" vocab-term="Funding acquisition">Funding acquisition</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/" vocab-term="Project administration">Project administration</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/resources/" vocab-term="Resources">Resources</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/" vocab-term="Supervision">Supervision</role><role vocab="credit" vocab-identifier="https://credit.niso.org/" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/" vocab-term="Writing &#x02013; review &#x00026; editing">Writing &#x02013; review &#x00026; editing</role></contrib><aff id="aff0001">Cancer Signaling &#x00026; Microenvironment Program, <institution-wrap><institution>Fox Chase Cancer Center</institution></institution-wrap>, <city>Philadelphia</city>, <state>PA</state>, <country>USA</country></aff></contrib-group><author-notes><corresp id="an0001">CONTACT Jonathan Chernoff <email xlink:href="mailto:J_Chernoff@fccc.edu">J_Chernoff@fccc.edu</email> Cancer Signaling &#x00026; Microenvironment Program, Fox Chase Cancer Center, 333 Cottman Ave, <addr-line>333 Cottman Avenue</addr-line>, <city>Philadelphia</city>, <state>PA</state>
<postal-code>19111</postal-code>, <country>USA</country></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>21</day><month>5</month><year>2025</year></pub-date><pub-date date-type="collection" publication-format="electronic"><year>2024</year></pub-date><pub-date pub-type="pmc-release"><day>21</day><month>5</month><year>2025</year></pub-date><volume>15</volume><issue>1</issue><fpage seq="3">1</fpage><lpage>14</lpage><pub-history><event event-type="tagger"><event-desc>Integra</event-desc><date><day>21</day><month>5</month><year>2025</year></date></event><event event-type="final"><event-desc>Integra</event-desc><date><day>21</day><month>5</month><year>2025</year></date></event><event event-type="received"><date><day>07</day><month>2</month><year>2025</year></date></event><event event-type="revised"><date><day>06</day><month>4</month><year>2025</year></date></event><event event-type="accepted"><date><day>06</day><month>5</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#x000a9; 2025 The Author(s). Published by Informa UK Limited, trading as Taylor &#x00026; Francis Group.</copyright-statement><copyright-year>2025</copyright-year><copyright-holder>The Author(s)</copyright-holder><license><ali:license_ref xmlns:ali="http://www.niso.org/schemas/ali/1.0/" specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="KSGT_15_2505977.pdf"/><abstract><title>ABSTRACT</title><p>RAC1 is a small 21 kDa RHO GTPase that plays a pivotal role in regulating actin cytoskeletal dynamics and cell growth. Alterations in the activity of RAC1 are implicated in a range of diseases, including cancer. Increased RAC1 activity, due to overexpression and/or activating mutations, drives transcriptional upregulation, reactive oxygen species production, mesenchymal-to-epithelial transition, membrane ruffling, and uncontrolled cell proliferation, which are hallmarks of an oncogenic phenotype. While RAC1-activating mutations alone do not appear sufficient to transform cells, their combination with other common mutations, such as BRAF, NRAS, or NF1, have been linked to drug resistance and significantly worsen patient prognosis and hinder treatment responses. The precise mechanisms underlying drug resistance, and the regulation of <italic toggle="yes">RAC1</italic> splicing remain poorly understood. RAC1 is a challenging therapeutic target due to its ubiquitous presence and essential cellular functions. To date, there are no established standard treatments for cancers that harbour an additional RAC1 mutation or for RAC1-mediated drug resistance. Current experimental strategies aim to target RAC1 localization, its activators (<italic toggle="yes">e.g</italic>. guanine nucleotide exchange factors) and downstream effectors. Regulating RAC1 expression by targeting epigenetic regulators, and direct targeting of RAC1 itself, may also be possible in the near future.</p></abstract><kwd-group kwd-group-type="author"><title>KEYWORDS</title><kwd>Signal transduction</kwd><kwd>cancer</kwd><kwd>RHO GTPases</kwd><kwd>RAC1</kwd><kwd>drug resistance</kwd></kwd-group><support-group><funding-group><award-group><funding-source>
<institution-wrap><institution>National Cancer Institute</institution><institution-id institution-id-type="open-funder-registry">10.13039/100000054</institution-id></institution-wrap>
</funding-source><award-id>CA227184</award-id><award-id>CA06927</award-id></award-group><award-group><funding-source>
<institution-wrap><institution>Melanoma Research Foundation</institution><institution-id institution-id-type="open-funder-registry">10.13039/100002224</institution-id></institution-wrap>
</funding-source><award-id>MRF585198</award-id></award-group><funding-statement>We received funding support from the National Cancer Institute [CA227184, CA06927] and the Melanoma Research Foundation [MRF585198].</funding-statement></funding-group></support-group><counts><fig-count count="2"/><table-count count="1"/><ref-count count="157"/><page-count count="14"/><word-count count="3891"/></counts></article-meta></front><body><p>Small GTPases (20&#x02013;30 kDa) are hydrolases that function as binary on-and-off switches that cycle between an active guanosine triphosphate (GTP)-bound state and an inactive guanosine diphosphate (GDP)-bound state [<xref rid="cit0001" ref-type="bibr">1</xref>]. These low molecular weight proteins (20&#x02013;30 kDa) regulate a vast number of cellular processes involved in cell proliferation, survival, metabolism, and motility [<xref rid="cit0002" ref-type="bibr">2&#x02013;5</xref>]. Small GTPases can be grouped according to their sequence and function into five major families: RAS, RHO, ARF, RAN and RAB [<xref rid="cit0006" ref-type="bibr">6</xref>]. The RHO GTPase subfamily &#x02013; subdivided into seven subfamilies: RHO, RAC, CDC42, RND, RHOD, RHOBTB, and RHOH &#x02013; is best known for its role in actin dynamics and cell polarity [<xref rid="cit0003" ref-type="bibr">3</xref>]. The RAC GTPase subfamily consists of four members, RHOG and the Ras-Related C3 Botulinum Toxin Substrates RAC1, RAC2, RAC3 [<xref rid="cit0003" ref-type="bibr">3</xref>,<xref rid="cit0007" ref-type="bibr">7</xref>].</p><p>The <italic toggle="yes">RAC1</italic> gene is localized on chromosome 7 (7p22.1) and it encodes a 192 amino acid, 21 kDa, plasma membrane-associated protein [<xref rid="cit0001" ref-type="bibr">1</xref>]. The GC-rich <italic toggle="yes">RAC1</italic> promoter is localized 113&#x02013;30 bp upstream of <italic toggle="yes">RAC1</italic> transcription site and like typical housekeeping genes, it does not have a TATA- and a CCAAT-box [<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0008" ref-type="bibr">8</xref>]. <italic toggle="yes">RAC1</italic> contains seven exons, that can produce two proteins through alternative splicing: RAC1 (exons 1&#x02013;6), and the splicing variant RAC1B that includes the expression of an additional exon 3B (exons 1&#x02013;3, 3b, 4&#x02013;6) (<xref rid="f0001" ref-type="fig">Figure 1(a)</xref>) [<xref rid="cit0011" ref-type="bibr">11</xref>]. RAC1 structure contains two mobile regulatory switch domains, Switch I (residues 25 to 39), and Switch II (residues 57 to 75) that undergo conformational changes during the exchange of GDP/GTP and allow RAC1 to interact with its effector proteins and activate downstream signalling molecules [<xref rid="cit0012" ref-type="bibr">12</xref>]. Like the RAS superfamily, RAC1&#x000a0;has a highly conserved central guanine nucleotide-binding domain pocket that includes a) the phosphate-binding sequences GDGAVGKT (residues 10&#x02013;17) and DTAG (residues 57&#x02013;60), and b) the guanine recognition loop TK(L/K)D (residues 114&#x02013;117) and SAL (residues 158&#x02013;160) [<xref rid="cit0013" ref-type="bibr">13</xref>,<xref rid="cit0014" ref-type="bibr">14</xref>]. RAC1&#x02019;s globular structure folds into a compact six strand-&#x003b2;-sheets and six &#x003b1;-helix protein (<xref rid="f0001" ref-type="fig">Figure 1(a)</xref>).
<fig position="float" id="f0001" fig-type="figure"><label>Figure 1.</label><caption><p>RAC1 mutations and their association with diverse diseases. A) <italic toggle="yes">RAC1</italic>, localized on chromosome 7 (7p22.1), encodes a 192 amino acid 21 kDa protein. The <italic toggle="yes">RAC1</italic> promoter is localized 113&#x02013;30 bp upstream the transcription initiation site. <italic toggle="yes">RAC1</italic> has 7 exons that can produce two proteins: RAC1 (exons 1&#x02013;6) and the fast-cycling isoform RAC1B (exons 1&#x02013;3, 3b, 4&#x02013;6). Exon 3b adds a 19 amino acid in-frame insertion after the switch-II domain (orange) that induces an open switch I conformation and a highly mobile switch II. RAC1s tertiary structure consists of a 6 strand &#x003b2;-sheet domain surrounded by six &#x003b1; helices. RAC1 (PDB-3TH5) [<xref rid="cit0009" ref-type="bibr">9</xref>], and RAC1B (PDB-1RYF) [<xref rid="cit0010" ref-type="bibr">10</xref>] protein models were generated using swissmodel.Expasy.org B) RAC1 is tightly regulated: decreased RAC1 signalling is related to neurodegenerative disorders, mental retardation and micro- and macrocephaly, epilepsy and cardiovascular diseases; while increased activity of RAC1 can accelerate cells oncogenic phenotype, confer drug resistance tumours and worsen patients prognosis. Created in BioRender. Uribe, C. (2025) <ext-link xlink:href="https://bioRender.com/e76i718" ext-link-type="uri">https://bioRender.com/e76i718</ext-link></p></caption><alternatives><graphic xlink:href="KSGT_A_2505977_F0001_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="KSGT_A_2505977_F0001_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>RAC1 activity is tightly controlled by growth factors, phospholipids, integrins, and upstream regulators [<xref rid="cit0015" ref-type="bibr">15</xref>]. RAC1 activity can be decreased by GTPase-activating proteins (GAPs), which accelerate hydrolysis of GTP to GDP, resulting in a decrease of active RAC1-GTP; or by Guanine-nucleotide dissociation inhibitors (GDIs), which (a) sequester inactive RAC1 in the cytoplasm, preventing it from exchanging GDP to GTP; (b) interact with RAC1-GTP and inhibit GTP hydrolysis and its interaction with effector proteins; (c) and bury the hydrophobic prenyl group of RAC1 within a hydrophobic groove of its immunoglobulin&#x02013;like domain, sequestering RAC1 in a cytosolic soluble pool and preventing it from anchoring to the plasma membrane [<xref rid="cit0016" ref-type="bibr">16</xref>]. GDIs also restrict RHO GTPases access to activating guanine-nucleotide exchange factors (GEFs) and GTPase activating proteins (GAPs) [<xref rid="cit0017" ref-type="bibr">17</xref>]. GDIs have a phosphorylation-mediated release mechanism that controls and coordinates RHO GTPase activation. Phosphorylation of the RAC1&#x02013;RHOGDI&#x003b1; complex by PAK1 (p21-activated kinase 1) or by the calcium-dependent PKC&#x003b1; (Protein kinase C &#x003b1;) decreases the stability of the complex and induces conformational changes that release RAC1 and allow it to be further activated or transported [<xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0018" ref-type="bibr">18</xref>].</p><p>RAC1 requires the help of guanine-nucleotide exchange factors (GEFs) to exchange GDP for GTP. The binding of a GEF to RAC1 induces conformational changes in the switch regions and the phosphate binding area that stimulate the release of GDP. Then the GEF is displaced by the subsequent binding of a GTP molecule [<xref rid="cit0019" ref-type="bibr">19</xref>]. There are&#x02009;~85 GEFs capable of promoting GDP/GTP exchange activity on RHO GTPases, and about half can act on RAC isoforms (<xref rid="t0001" ref-type="table">Table 1</xref>). Most RAC-GEFs belong to the Diffuse B-cell lymphoma (DBL)-like class, which has a prototypical N-terminal DH (DBL homology) domain responsible for GDP/GTP exchange activity, often in tandem with a PH (pleckstrin homology) domain that acts as binding sites from PI3K lipid products [<xref rid="cit0062" ref-type="bibr">62</xref>]. Mutated or overexpressed GEFs can elevate the rate of GDP/GTP exchange of RAC1 resulting in oncogenic phenotypes that include increased cell invasion, drug resistance and metastasis [<xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0064" ref-type="bibr">64</xref>].<table-wrap position="float" id="t0001"><label>Table 1.</label><caption><p>RAC1 nucleotide exchange factors (GEF) specificity.</p></caption><!--OASIS TABLE HERE--><table frame="hsides" rules="groups"><colgroup><col width="1*" align="left"/><col width="1*" align="left"/><col width="1*" align="center"/></colgroup><thead><tr><th align="left">GEF</th><th align="center">Specificity</th><th align="center">Reference</th></tr></thead><tbody><tr><td align="left">KALIRIN 5/7</td><td align="left">RAC</td><td align="center">[<xref rid="cit0020" ref-type="bibr">20</xref>]</td></tr><tr><td align="left">TIAM1/TIAM2</td><td align="left">RAC</td><td align="center">[<xref rid="cit0021" ref-type="bibr">21&#x02013;24</xref>]</td></tr><tr><td align="left">SOLO/TRIO8</td><td align="left">RAC</td><td align="center">[<xref rid="cit0020" ref-type="bibr">20</xref>]</td></tr><tr><td align="left">DOCK1/2</td><td align="left">RAC</td><td align="center">[<xref rid="cit0025" ref-type="bibr">25&#x02013;28</xref>]</td></tr><tr><td align="left">P-REX2</td><td align="left">RAC</td><td align="center">[<xref rid="cit0029" ref-type="bibr">29</xref>]</td></tr><tr><td align="left">b-PIX/COOL1</td><td align="left">RAC/CDC42</td><td align="center">[<xref rid="cit0027" ref-type="bibr">27</xref>,<xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0031" ref-type="bibr">31</xref>]</td></tr><tr><td align="left">FGD5</td><td align="left">RAC/CDC42</td><td align="center">[<xref rid="cit0028" ref-type="bibr">28</xref>,<xref rid="cit0032" ref-type="bibr">32</xref>]</td></tr><tr><td align="left">PLEKHG1/G2/G3</td><td align="left">RAC/CDC42</td><td align="center">[<xref rid="cit0033" ref-type="bibr">33&#x02013;35</xref>]</td></tr><tr><td align="left">ASEF1/2</td><td align="left">RAC/CDC42</td><td align="center">[<xref rid="cit0036" ref-type="bibr">36</xref>,<xref rid="cit0037" ref-type="bibr">37</xref>]</td></tr><tr><td align="left">DOCK6/7/10</td><td align="left">RAC/CDC42</td><td align="center">[<xref rid="cit0038" ref-type="bibr">38</xref>]</td></tr><tr><td align="left">VAV1/2/3</td><td align="left">RAC/CDC42</td><td align="center">[<xref rid="cit0039" ref-type="bibr">39</xref>,<xref rid="cit0040" ref-type="bibr">40</xref>]</td></tr><tr><td align="left">ARHGEF39</td><td align="left">RAC/RHO</td><td align="center">[<xref rid="cit0023" ref-type="bibr">23</xref>]</td></tr><tr><td align="left">KALIRIN 12</td><td align="left">RAC/RHO</td><td align="center">[<xref rid="cit0020" ref-type="bibr">20</xref>]</td></tr><tr><td align="left">TRIO FL</td><td align="left">RAC/RHO</td><td align="center">[<xref rid="cit0020" ref-type="bibr">20</xref>]</td></tr><tr><td align="left">Ephexin1/3/4/5</td><td align="left">RAC/CDC42/RHO</td><td align="center">[<xref rid="cit0041" ref-type="bibr">41&#x02013;43</xref>]</td></tr><tr><td align="left">DEF6</td><td align="left">RAC/CDC42/RHO</td><td align="center">[<xref rid="cit0044" ref-type="bibr">44&#x02013;46</xref>]</td></tr><tr><td align="left">P-REX1</td><td align="left">RAC/CDC42/RHO</td><td align="center">[<xref rid="cit0047" ref-type="bibr">47&#x02013;51</xref>]</td></tr><tr><td align="left">a-PIX/COOL2</td><td align="left">RAC/CDC42/RHO</td><td align="center">[<xref rid="cit0030" ref-type="bibr">30</xref>,<xref rid="cit0052" ref-type="bibr">52</xref>]</td></tr><tr><td align="left">FARP1/FERM</td><td align="left">RAC/CDC42/RHO</td><td align="center">[<xref rid="cit0023" ref-type="bibr">23</xref>,<xref rid="cit0053" ref-type="bibr">53</xref>,<xref rid="cit0054" ref-type="bibr">54</xref>]</td></tr><tr><td align="left">GEFT (p63RhoGEF)</td><td align="left">RAC/CDC42/RHO</td><td align="center">[<xref rid="cit0055" ref-type="bibr">55</xref>]</td></tr><tr><td align="left">ARHGEF16</td><td align="left">RAC/CDC42/RHO</td><td align="center">[<xref rid="cit0043" ref-type="bibr">43</xref>]</td></tr><tr><td align="left">Ras-GRF1/2</td><td align="left">RAC/RAS</td><td align="center">[<xref rid="cit0056" ref-type="bibr">56&#x02013;59</xref>]</td></tr><tr><td align="left">SOS1/2</td><td align="left">RAC/RAS</td><td align="center">[<xref rid="cit0060" ref-type="bibr">60</xref>,<xref rid="cit0061" ref-type="bibr">61</xref>]</td></tr></tbody></table></table-wrap></p><p>Cytosolic RAC1 can be mobilized to the plasma membrane, where it regulates actin dynamics and membrane protrusions, thereby controlling cell motility and adhesion [<xref rid="cit0065" ref-type="bibr">65</xref>,<xref rid="cit0066" ref-type="bibr">66</xref>], or it can migrate to the nucleus, where it regulates nuclear membrane organization, enhances cell cycle progression, division, and increases transcriptional activation of Wnt target genes [<xref rid="cit0067" ref-type="bibr">67&#x02013;71</xref>]. RAC1 subcellular localization unbalance and abnormal nuclear accumulation has been linked to cancer progression and invasion [<xref rid="cit0071" ref-type="bibr">71&#x02013;73</xref>]. Cells with nuclear-export deficiencies (including the knockdown of the B23 nuclear chaperone protein that exports RAC1 from the nucleus to the cytoplasm) accumulate RAC1 in the nucleus, creating an unbalance that increases RHO/ROCK signalling and results in increased cell proliferation and migration [<xref rid="cit0073" ref-type="bibr">73</xref>]. RAC1 accumulation in the nuclei has been found in PC3, LM4175 lung carcinoma and OCI-AML3 acute myeloid leukaemia cells lines. Additionally, RAC1 nuclear localization is also predominantly detected in prostate cancer tissues compared to benign tissues [<xref rid="cit0073" ref-type="bibr">73</xref>]. In breast cancer, RAC1 can also interact with oestrogen receptors &#x003b1; (ER&#x003b1;) that are predominantly found in the cell&#x02019;s nucleus. RAC1 and ER&#x003b1; protein levels appear to be positively correlated, with RAC1 modulating transcriptional activity of ER&#x003b1; [<xref rid="cit0074" ref-type="bibr">74</xref>]. RAC1 targeting has shown to reduce ER transcriptional activity and cell proliferation on ER positive breast cancer [<xref rid="cit0074" ref-type="bibr">74</xref>,<xref rid="cit0075" ref-type="bibr">75</xref>].</p><p>RAC1 is a key signalling molecule that is ubiquitously expressed in human tissues [<xref rid="cit0014" ref-type="bibr">14</xref>,<xref rid="cit0076" ref-type="bibr">76</xref>]. RAC1 regulates various downstream effector proteins that contribute to epithelial differentiation, cellular motility, cytoskeletal reorganization, cell-to-cell adhesion, proliferation, cell cycle, phagocytosis, NADPH, ROS activity, and inflammatory responses [<xref rid="cit0077" ref-type="bibr">77</xref>]. RAC1 integrates cellular signals to control actin dynamics and migration of various immune cells, including neutrophils, B cells and macrophages influencing their function and distribution during inflammation [<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0079" ref-type="bibr">79</xref>]. RAC1 also reorganizes neuron cytoskeletons contributing to dendritic spine formation, maintenance, morphogenesis and synaptic plasticity [<xref rid="cit0080" ref-type="bibr">80</xref>]. In adipose tissue and skeletal muscle, RAC1 participates in insulin response, facilitating the translocation of GLUT4 glucose transporter vesicles to the plasma membrane, thereby allowing glucose entry into cells and decreasing blood glucose [<xref rid="cit0081" ref-type="bibr">81</xref>,<xref rid="cit0082" ref-type="bibr">82</xref>]. RAC1 forms part of the NAPDH oxidase complex that participates in oxidative metabolism and reactive oxygen production and can further influence mitochondrial function and inflammatory processes [<xref rid="cit0083" ref-type="bibr">83&#x02013;85</xref>]. Therefore, anomalous or dysfunctional RAC1 signalling is implicated in various human pathologic conditions, including neurodegenerative disorders, mental retardation and micro-and macrocephaly, epilepsy, cardiovascular diseases, diabetes and cancer [<xref rid="cit0006" ref-type="bibr">6</xref>,<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0085" ref-type="bibr">85&#x02013;91</xref>]. <italic toggle="yes">RAC1</italic> missense mutations tend to cause developmental delay and brain malformations, while <italic toggle="yes">RAC1</italic> deletion in mice and drosophila leads to embryonic lethality [<xref rid="cit0090" ref-type="bibr">90</xref>,<xref rid="cit0092" ref-type="bibr">92</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>]. The dominant negative mutant RAC1<sup>T17N</sup> affinity for GTP is 10 times lower than for GDP, and is predominantly found in either a nucleotide-free state or bound to GDP in an inactive state [<xref rid="cit0094" ref-type="bibr">94</xref>]. Unlike RAC1, RAC1<sup>T17N</sup> in not regulated by RhoGDIs. However, it can strongly associate with GEFs, thereby competing and reducing wild-type RAC1 activation [<xref rid="cit0095" ref-type="bibr">95</xref>]. Furthermore, RAC1<sup>T17N</sup> downstream signalling appears to be interrupted since it fails to interact with key effectors such as PAK1 [<xref rid="cit0063" ref-type="bibr">63</xref>,<xref rid="cit0095" ref-type="bibr">95&#x02013;97</xref>]. In drosophila, expression of RAC1<sup>T17N</sup> disrupts fusion and morphology in drosophila myoblasts affecting muscle formation [<xref rid="cit0093" ref-type="bibr">93</xref>] (<xref rid="f0001" ref-type="fig">Figure 1(b)</xref>).</p><sec disp-level="1" id="s0002"><title>RAC1 mutations in cancer</title><p>In human cancers, gain of function mutations in <italic toggle="yes">RAC1</italic> result in increased RAC1 signalling which contributes to cancer cell growth and invasion of local and distant tissues. <italic toggle="yes">RAC1</italic> mutations promote tumorigenesis in melanoma, non-small cell lung cancer, breast cancer, prostate cancer, colorectal cancer, head and neck cancer, testicular germ cell tumours, glioblastoma multiforme, hepatocellular carcinoma and thyroid carcinoma among others [<xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0086" ref-type="bibr">86</xref>,<xref rid="cit0098" ref-type="bibr">98&#x02013;104</xref>]. Activated RAC1 mutations accelerate tumour growth, induces epithelial&#x02013;mesenchymal transition (EMT), increases angiogenesis, and influences tumour microenvironment-mediated immune escape driving tumour metastasis and causing treatment failures [<xref rid="cit0066" ref-type="bibr">66</xref>,<xref rid="cit0086" ref-type="bibr">86</xref>,<xref rid="cit0098" ref-type="bibr">98</xref>,<xref rid="cit0105" ref-type="bibr">105&#x02013;108</xref>]. Both <italic toggle="yes">in vitro</italic> and <italic toggle="yes">in vivo</italic> studies indicate that wild-type RAC1&#x000a0;has an essential role in RAS-mediated transformation [<xref rid="cit0109" ref-type="bibr">109</xref>], and RAC1 overexpression is linked to worse prognosis in cancer patients [<xref rid="cit0078" ref-type="bibr">78</xref>,<xref rid="cit0110" ref-type="bibr">110&#x02013;112</xref>]. Activated forms of RAC1 influence the overall survival and drug resistance in different types of cancer, and RAC1 expression levels have been proposed as a prognostic biomarker for patient survival [<xref rid="cit0098" ref-type="bibr">98</xref>,<xref rid="cit0108" ref-type="bibr">108</xref>,<xref rid="cit0111" ref-type="bibr">111</xref>,<xref rid="cit0113" ref-type="bibr">113&#x02013;116</xref>]. RAC1 gain-of-function mutations have been reported to increase tumours resistance to chemotherapy, chemo-radiation, targeted therapy and anti-hormonal therapy [<xref rid="cit0105" ref-type="bibr">105</xref>,<xref rid="cit0106" ref-type="bibr">106</xref>]. Such mutations also result in resistance to targeted therapy BRAK and MEK drugs in melanoma [<xref rid="cit0108" ref-type="bibr">108</xref>,<xref rid="cit0111" ref-type="bibr">111</xref>,<xref rid="cit0115" ref-type="bibr">115</xref>], resistance to cisplatin in oesophageal squamous cell carcinoma [<xref rid="cit0117" ref-type="bibr">117</xref>] and to irradiation therapies in lung cancer [<xref rid="cit0118" ref-type="bibr">118</xref>]. RAC1<sup>Q61L</sup> and RAC1<sup>G12V</sup> are constitutively active forms of RAC1 that are locked in the GTP-bound active state and are unaffected by GAPs and GDIs [<xref rid="cit0017" ref-type="bibr">17</xref>,<xref rid="cit0093" ref-type="bibr">93</xref>,<xref rid="cit0119" ref-type="bibr">119</xref>,<xref rid="cit0120" ref-type="bibr">120</xref>]. Other mutations such as RAC1<sup>P29S</sup> and RAC1<sup>A159V</sup> are fast cycling mutations in which, unlike constitutively activating mutations, the intrinsic GTP hydrolysis ability is still influenced by GDIs. RAC1<sup>A159V</sup> most commonly occurs in head and neck cancer, while RAC1<sup>P29S</sup> is a known hotspot mutation in malignant melanoma [<xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0086" ref-type="bibr">86</xref>,<xref rid="cit0099" ref-type="bibr">99</xref>]. RAC1 activating mutations alone are insufficient to initiate carcinogenesis in skin, colorectal and lung cancer, but cooperation with <italic toggle="yes">BRAF</italic> or <italic toggle="yes">KRAS</italic> mutations results in enhanced proliferation and accelerated tumour growth [<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0087" ref-type="bibr">87</xref>,<xref rid="cit0101" ref-type="bibr">101</xref>,<xref rid="cit0104" ref-type="bibr">104</xref>,<xref rid="cit0121" ref-type="bibr">121</xref>].</p></sec><sec disp-level="1" id="s0003"><title>RAC1B</title><p>The <italic toggle="yes">RAC1</italic> gene has an additional exon 3b that is usually not transcribed. This exon comprises 57 nucleotides which, through alternative RNA splicing generate a fast-cycling form of RAC1 known as RAC1B [<xref rid="cit0098" ref-type="bibr">98</xref>,<xref rid="cit0122" ref-type="bibr">122</xref>,<xref rid="cit0123" ref-type="bibr">123</xref>]. This 19-amino acid in-frame is inserted after the switch-II domain and induces an open switch I conformation, a highly mobile switch II, and creates two potential threonine phosphorylation sites (<xref rid="f0001" ref-type="fig">Figure 1(a)</xref>) [<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0011" ref-type="bibr">11</xref>]. RAC1B is also regulated by GAPs and GEFs, but cannot be sequestered in the cytoplasm by GDIs, consequently, most RAC1B will remain active [<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0012" ref-type="bibr">12</xref>,<xref rid="cit0015" ref-type="bibr">15</xref>]. RAC1B expression keeps RAC1 signalling pathways activated, including the tumour-associated signalling pathways, and enhances transcription, cell&#x02013;cell adhesion, cell invasiveness and motility [<xref rid="cit0124" ref-type="bibr">124</xref>]. RAC1B is almost exclusively expressed in tumour tissue and is associated with worse overall survival and drug resistance in cancer patients [<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0098" ref-type="bibr">98</xref>,<xref rid="cit0103" ref-type="bibr">103</xref>,<xref rid="cit0113" ref-type="bibr">113</xref>,<xref rid="cit0114" ref-type="bibr">114</xref>,<xref rid="cit0121" ref-type="bibr">121</xref>,<xref rid="cit0125" ref-type="bibr">125&#x02013;128</xref>].</p><p><italic toggle="yes">RAC1</italic> alternative splicing regulation is poorly understood; however, a recent publication implicated a long noncoding RNA (LncH19) in this process [<xref rid="cit0129" ref-type="bibr">129</xref>]. In colorectal cancer cells, Cordaro et al. showed that LncH19 is required for RAC1B expression through its association with RBFOX2 and hnRNPM splicing factors. Consistently, CRC patient biopsy samples showed a positive correlation between lncH19 and RAC1B expression [<xref rid="cit0129" ref-type="bibr">129</xref>]. In CRC, RAC1B can also migrate to the nucleus, where it associates with the &#x003b2;-catenin-TCF complex and increases expression of cyclins and pro-tumour signalling [<xref rid="cit0130" ref-type="bibr">130</xref>]. Besides being a fast-cycling isoform of RAC1, it appears that RAC1B structural modifications protect it from proteasomal degradation. The HACE1 E3 ubiquitin ligase is a tumour suppressor that ubiquinates active RAC1 at the Lys147 residue, leading to its degradation. The loss of HACE1 leads to an increase of RAC1 activity that contributes to tumour growth, cell migration and cancer progression [<xref rid="cit0084" ref-type="bibr">84</xref>,<xref rid="cit0131" ref-type="bibr">131&#x02013;133</xref>]. Unlike RAC1<sup>WT</sup> and RAC1<sup>L61</sup>, RAC1B HACE1-mediated polyubiquitination is minimal, so the protein does not rapidly degrade, and its pro-tumorigenic effects persist [<xref rid="cit0131" ref-type="bibr">131</xref>,<xref rid="cit0134" ref-type="bibr">134</xref>]. Additionally, when compared to RAC1<sup>WT</sup> and RAC1 point mutations, RAC1B shows a diminished ability to signal through PAK1, AKT1, and Jun N-terminal kinase (JNK) [<xref rid="cit0127" ref-type="bibr">127</xref>], which is also a critical regulator of RAC1 ubiquitination [<xref rid="cit0119" ref-type="bibr">119</xref>,<xref rid="cit0127" ref-type="bibr">127</xref>,<xref rid="cit0134" ref-type="bibr">134</xref>].</p><p>RAC1B expression has been found in skin and epithelial tissues from the intestinal tract, breast carcinoma, HCC, lung cancer, NSCLC, pancreatic adenocarcinoma, thyroid cancers and papillary thyroid carcinomas [<xref rid="cit0001" ref-type="bibr">1</xref>,<xref rid="cit0010" ref-type="bibr">10</xref>,<xref rid="cit0011" ref-type="bibr">11</xref>,<xref rid="cit0098" ref-type="bibr">98</xref>,<xref rid="cit0122" ref-type="bibr">122</xref>,<xref rid="cit0126" ref-type="bibr">126</xref>,<xref rid="cit0128" ref-type="bibr">128</xref>]. RAC1B overexpression synergizes with activating <italic toggle="yes">BRAF</italic> and <italic toggle="yes">KRAS</italic> mutations, worsening the prognosis in follicular thyroid carcinomas, colorectal cancer, and lung adenocarcinomas [<xref rid="cit0101" ref-type="bibr">101</xref>,<xref rid="cit0103" ref-type="bibr">103</xref>,<xref rid="cit0104" ref-type="bibr">104</xref>,<xref rid="cit0121" ref-type="bibr">121</xref>]. RAC1B is presumed to be responsible for chemoresistance to doxorubicin and trastuzumab, tumour recurrence and metastasis in breast cancer stem cells (BCSCs). RAC1B silencing in BCSCs reverted tumours sensitivity to doxorubicin [<xref rid="cit0098" ref-type="bibr">98</xref>]. RAC1B overexpression is also linked to CRC resistance to cetuximab and oxaliplatin, and RAC1B knockdown re-sensitizes tumours to oxaliplatin treatment <italic toggle="yes">in vivo</italic> [<xref rid="cit0113" ref-type="bibr">113</xref>,<xref rid="cit0114" ref-type="bibr">114</xref>]. For these reasons, RAC1B expression may serve as a specific molecular target to re-sensitize chemo-resistant tumours and as a prognostic marker to predict patients&#x02019; outcomes and treatment response [<xref rid="cit0098" ref-type="bibr">98</xref>,<xref rid="cit0103" ref-type="bibr">103</xref>,<xref rid="cit0135" ref-type="bibr">135</xref>].</p></sec><sec disp-level="1" id="s0004"><title>RAC1<sup>P29S</sup> and its role in mediating drug resistance</title><p><italic toggle="yes">RAC1</italic> mutations are present in 2&#x02013;9% melanomas, usually in association with activation mutations in <italic toggle="yes">BRAF</italic> or <italic toggle="yes">NRAS</italic>, or inactivating mutations in <italic toggle="yes">NF1</italic> [<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0087" ref-type="bibr">87</xref>,<xref rid="cit0111" ref-type="bibr">111</xref>]. The overwhelming majority of <italic toggle="yes">RAC1</italic> mutations in melanoma consist in a change from proline to serine (c.85C &#x0003e; T) in position 29 [<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0087" ref-type="bibr">87</xref>,<xref rid="cit0111" ref-type="bibr">111</xref>]. RAC1<sup>P29S</sup> is the third most common protein-coding hotspot mutation in melanoma after BRAF<sup>V600E</sup> and NRAS<sup>Q61R/L/K</sup>. The P29S mutation is located within switch I and results in an increased protein flexibility that facilitates GTP interaction and increases nucleotide hydrolyzation [<xref rid="cit0012" ref-type="bibr">12</xref>]. A direct consequence of faster cycling between GDP and GTP is the increase in interaction with effector proteins and cell signalling through Group A PAKs, phosphatidyl inositol-3 kinase (PI3K)-&#x003b2;, and serum response factor (SRF)/myocardin-related transcription factor (MRTF) (<xref rid="f0002" ref-type="fig">Figure 2</xref>) [<xref rid="cit0086" ref-type="bibr">86</xref>,<xref rid="cit0136" ref-type="bibr">136</xref>,<xref rid="cit0137" ref-type="bibr">137</xref>]. <italic toggle="yes">RAC1</italic> mutations are insufficient to drive melanoma and are almost always found with other activating MAP kinase hot spot mutations, most frequently <italic toggle="yes">NRAS</italic> (47%), <italic toggle="yes">BRAF</italic> [<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0087" ref-type="bibr">87</xref>,<xref rid="cit0111" ref-type="bibr">111</xref>], or <italic toggle="yes">NF1</italic> [<xref rid="cit0009" ref-type="bibr">9</xref>,<xref rid="cit0108" ref-type="bibr">108</xref>,<xref rid="cit0111" ref-type="bibr">111</xref>,<xref rid="cit0138" ref-type="bibr">138</xref>]. Like RAC1B, RAC1<sup><italic toggle="yes">P29S</italic></sup> mutations synergize with <italic toggle="yes">BRAF</italic> and <italic toggle="yes">NRAS</italic> mutations activating the MAPK signalling pathway conferring resistance to targeted therapy drugs such as vemurafenib and dabrafenib monotherapies [<xref rid="cit0108" ref-type="bibr">108</xref>,<xref rid="cit0111" ref-type="bibr">111</xref>,<xref rid="cit0115" ref-type="bibr">115</xref>,<xref rid="cit0116" ref-type="bibr">116</xref>]. In addition, RAC1<sup><italic toggle="yes">P29S</italic></sup> melanoma can evade immune surveillance by over expressing programmed cell death ligand-1 [<xref rid="cit0139" ref-type="bibr">139</xref>].
<fig position="float" id="f0002" fig-type="figure"><label>Figure 2.</label><caption><p>Targeting RAC1 regulation and downstream effectors. RAC1&#x02019;s GDP-to-GTP exchange is stimulated by guanine-nucleotide exchange factors (GEFs) and inhibited by GTPase activating proteins (GAPs) which accelerate the intrinsic hydrolysis of GTP to GDP; or by GDP-dissociation inhibitors (GDIs) that sequester RAC1 in the cytoplasm. Drugs against RAC1 target its localization, its guanine nucleotide effectors (GEFs), interact directly with RAC1 or RAC1-GTP, or target RAC1 downstream effectors. Created in BioRender. Uribe, C. (2025) <ext-link xlink:href="https://BioRender.com/e76i718" ext-link-type="uri">https://BioRender.com/e76i718</ext-link>.</p></caption><alternatives><graphic xlink:href="KSGT_A_2505977_F0002_OC" content-type="color" specific-use="web-only" position="float"/><graphic xlink:href="KSGT_A_2505977_F0002_PB" content-type="black-white" specific-use="print-only" position="float"/></alternatives></fig></p><p>Interestingly, the RAC1<sup>P29S</sup> protein, while conferring primary resistance to MEK inhibitors, renders melanoma cells vulnerable to CDK9 inhibitors such as dinaciclib [<xref rid="cit0140" ref-type="bibr">140</xref>]. RNA and protein profiles showed that RAC1<sup>P29S</sup> expression is associated with elevated activity in signalling enzymes that regulate the G2/M transition, including the cell-cycle activating kinases such as Aurora-A, Polo1-like kinase (PLK)1, WEE1, and CDK9 [<xref rid="cit0140" ref-type="bibr">140</xref>]. Cannon <italic toggle="yes">et al. 2023</italic> recently showed that, in a syngeneic, <italic toggle="yes">in vivo</italic> setting, expressing RAC1<sup>P29S</sup> in YUMM1.7 <italic toggle="yes">(Braf</italic><sup><italic toggle="yes">V600E</italic></sup>, <italic toggle="yes">Pten</italic><sup><italic toggle="yes">null</italic></sup>, <italic toggle="yes">Cdkn2d</italic><sup><italic toggle="yes">null</italic></sup>) murine melanoma cells, rendered them exquisitely sensitive to dinaciclib especially when combined with a checkpoint inhibitor (anti-PD1). This enhanced response is likely to be related to the upregulation of PD-L1 in cell lines with RAC1<sup>P29S</sup> mutation [<xref rid="cit0139" ref-type="bibr">139</xref>]. RAC1<sup>P29S</sup> status in melanoma may therefore represent an important predictive biomarker for both response to targeted drugs against BRAF and MEK resistance and to ICIs [<xref rid="cit0111" ref-type="bibr">111</xref>].</p></sec><sec disp-level="1" id="s0005"><title>Epigenetic regulation of RAC1 in cancer and brain disorders</title><p>Environmentally induced changes in gene expression can shape an individual&#x02019;s susceptibility to diseases. DNA methylation, histone methylation/acetylation, and non-coding RNA regulation of a specific chromatin region can lead to abnormal cell growth, cell death evasion, and metastasis [<xref rid="cit0141" ref-type="bibr">141</xref>], and identifying chromatin modulators that sustain tumour growth has emerged as a promising approach to treat cancer. Epigenetic regulation of <italic toggle="yes">RAC1</italic> appears to be implicated in metabolic diseases such as diabetes [<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0088" ref-type="bibr">88</xref>]; and cancer [<xref rid="cit0002" ref-type="bibr">2</xref>,<xref rid="cit0005" ref-type="bibr">5</xref>,<xref rid="cit0142" ref-type="bibr">142&#x02013;144</xref>] and psychiatric disorders, such as depression and substance abuse [<xref rid="cit0008" ref-type="bibr">8</xref>,<xref rid="cit0145" ref-type="bibr">145</xref>,<xref rid="cit0146" ref-type="bibr">146</xref>].</p><p>The G9a is a histone methyl transferase is overexpressed in many cancers and influences migration and invasiveness [<xref rid="cit0144" ref-type="bibr">144</xref>,<xref rid="cit0147" ref-type="bibr">147&#x02013;149</xref>]. G9a knockdown (shG9a) or activity inhibition in alveolar rhabdomyosarcoma (ARMS) upregulated PTEN, reduced phosphorylation of AKT, and decreased RAC1 activity, resulting in a decrease in cell proliferation and defective cell migration. shG9a tumour cells transfected with a RAC1<sup>Q61L</sup> (a constitutively active RAC1) expressing vector restored the oncogenic phenotype, suggesting that RAC1 is a key downstream effector of G9a [<xref rid="cit0144" ref-type="bibr">144</xref>].</p><p><italic toggle="yes">RAC1</italic> epigenetic alterations modulate behaviours across a range of cellular process and diseases. In mice, and in human post-mortem studies, chronic social defeat stress (CSDS) and depression reduced histone H3 acetylation, and enhanced methylation of H3K27 in the regions close to <italic toggle="yes">RAC1&#x02019;s</italic> promoter, causing decreased transcription of <italic toggle="yes">RAC1</italic> in the subcortical reward region of the <italic toggle="yes">nucleus accumbens</italic> (NAc). Downregulation of <italic toggle="yes">RAC1</italic> disrupted neurons actin dynamics, resulting in impaired synapsis and a depressed mice phenotype. <italic toggle="yes">RAC1</italic> knock down mice displayed antisocial behaviours, while <italic toggle="yes">RAC1</italic> overexpressing mice showed an anti-stress effect even after being subjected to bigger and stronger mice bullying, suggesting <italic toggle="yes">RAC1</italic> expression can help modulate depressive behaviours [<xref rid="cit0145" ref-type="bibr">145</xref>].</p></sec><sec disp-level="1" id="s0006"><title>Therapeutic perspectives</title><p>Until recently, small RHO GTPases including RAC1 were considered undruggable or, at best, difficult targets. To date, most attempts to inhibit RAC1 signalling have targeted either its localization (<italic toggle="yes">e.g</italic>., by attempting to impede its isoprenyation) using statins or GGTase inhibitors (GGTIs), or by blocking its effector, such as PAKs (Frax-1036), PI3Ks (TGX221, GSK2636771) or the MRTF/SRF complex (CCG203971) [<xref rid="cit0108" ref-type="bibr">108</xref>,<xref rid="cit0136" ref-type="bibr">136</xref>,<xref rid="cit0137" ref-type="bibr">137</xref>,<xref rid="cit0150" ref-type="bibr">150</xref>] (<xref rid="f0002" ref-type="fig">Figure 2</xref>). However, in the last decade, a number of small molecule inhibitors of RAC1&#x000a0;have been described, including NSC-23766, its derivatives MBQ-167and Ehop-016, as well as 1A&#x02013;116, GYS32661, EHT1864, and AZA-1 and AZA-97 [<xref rid="cit0150" ref-type="bibr">150</xref>]. The mechanisms of action of RAC1 inhibitors falls into two main types: those that impede GTP binding and RAC1 interaction with downstream effectors, maintaining RAC1 in an inactive state, such as MLS000532223 and EHT1864 [<xref rid="cit0151" ref-type="bibr">151</xref>,<xref rid="cit0152" ref-type="bibr">152</xref>]; and those that interfere with GEF/RAC1 interactions such as NSC-23766 [<xref rid="cit0153" ref-type="bibr">153</xref>,<xref rid="cit0154" ref-type="bibr">154</xref>] (<xref rid="f0002" ref-type="fig">Figure 2</xref>). RAC1 inhibition by NSC23766 induced G<sub>1</sub> cell cycle arrest and apoptosis in breast cancer cells and inhibited the growth of prostate PC-3 cancer cells. NSC-23766&#x000a0;has never been tested in a clinical setting due to its low potency and low tumour-targeting specificity [<xref rid="cit0155" ref-type="bibr">155</xref>,<xref rid="cit0156" ref-type="bibr">156</xref>]. Current assays using a polymeric nanoparticle drug delivery system loaded with NSC23766&#x000a0;have been shown to increase the drug concentration and retention in the tumour site in PC-3 bearing mice, resulting in a decrease in tumour growth without notable toxicity effects [<xref rid="cit0102" ref-type="bibr">102</xref>]. Inhibiting RAC1 with EHT1864 increased the effect of anti-breast cancer drugs in endocrine resistant breast cancer [<xref rid="cit0074" ref-type="bibr">74</xref>]. While these compounds continue to be studied in preclinical settings, at present there are, to our knowledge, no RAC1-specific inhibitors in clinical development.</p><p>The recent identification of direct inhibitors of RAS raise hope that similar approaches may yield small molecule inhibitors of RAC1. Recently, the Shokat lab has shown that, like KRAS, RAC1 contains a cryptic, highly dynamic pocket in the switch II region that is potentially druggable [<xref rid="cit0157" ref-type="bibr">157</xref>]. Using a RAC1<sup>G12C, K96H</sup> mutant, they found that the KRAS<sup>G12C</sup> inhibitors divarasib and MRTX1257 were able to bind RAC1, as well as RAC1<sup>P29S</sup>, and inhibit their ability to engage downstream effectors such as PAK1 and to propagate signals to the cytoskeleton in a dose dependent manner. While these proof-of-concept experiments were carried out with RAC1 mutations (<italic toggle="yes">i.e</italic>., RAC1<sup>G12C</sup>, alone or combined as RAC1<sup>G12C, K96H</sup>) that are rarely if ever encountered in human cancer, they point to the possibility of developing targeted inhibitors that act directly on cancer-relevant mutants such as RAC1<sup>G12V</sup> and RAC1<sup>P29S</sup> [<xref rid="cit0157" ref-type="bibr">157</xref>].</p><p>Finally, given the importance of maintaining a balance in RAC1 expression, transport, and signalling in cells, regulating epigenetic modifications of the <italic toggle="yes">RAC1</italic> gene could be useful as a therapeutic approach in cancer and other disorders.</p></sec><sec disp-level="1" id="s0007"><title>Conclusion</title><p>RAC1 is a signalling molecule that can be rapidly activated and deactivated, and that regulates a wide variety of processes in virtually all cells. RAC1 is a challenging therapeutic target, not only because of its structure, but because of its essentiality for many fundamental cell functions. For RAC1, as for many small GTPases, the challenge is to design new drugs to target specific mutations, the splicing mechanism, or to control downstream effector activity, without unduly disturbing the essential functions of WT RAC1. While past attempts to target RAC1 signalling have shown a modest degree of success, the potential of exploiting secondary pockets, as has been done for RAS and recently extended to RAC1, presents an intriguing opportunity for further drug development. Further explorations of <italic toggle="yes">RAC1</italic> epigenetic regulatory mechanisms might also suggest therapeutic opportunities. Finally, more work is needed to investigate how RAC1 expression and activity engenders immune escape mechanisms and affects immune cell populations.</p></sec></body><back><sec sec-type="COI-statement" disp-level="1" id="s0008"><title>Disclosure statement</title><p>No potential conflict of interest was reported by the author(s).</p></sec><sec sec-type="data-availability" disp-level="1" id="s0009"><title>Data availability statement</title><p>Data sharing is not applicable to this article as no new data were created or analysed in this study.</p></sec><ref-list><title>References</title><ref id="cit0001"><label>[1]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matos</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Skaug</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Marques</surname>
<given-names>B</given-names></string-name>, et al</person-group>. <article-title>Small GTPase Rac1: structure, localization, and expression of the human gene</article-title>. <source>Biochem Biophys Res Commun</source>. <year>2000</year>;<volume>277</volume>(<issue>3</issue>):<fpage>741</fpage>&#x02013;<lpage>751</lpage>. doi: <pub-id pub-id-type="doi">10.1006/bbrc.2000.3743</pub-id>
<comment>PubMed PMID: 11062023</comment>.<pub-id pub-id-type="pmid">11062023</pub-id>
</mixed-citation></ref><ref id="cit0002"><label>[2]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Berthold</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Schenkova</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Rivero</surname>
<given-names>F.</given-names></string-name></person-group>
<article-title>Rho GTPases of the RhoBTB subfamily and tumorigenesis</article-title>. <source>Acta Pharmacol Sin</source>. <year>2008</year>;<volume>29</volume>(<issue>3</issue>):<fpage>285</fpage>&#x02013;<lpage>295</lpage>. doi: <pub-id pub-id-type="doi">10.1111/j.1745-7254.2008.00773.x</pub-id>
<comment>PubMed PMID: 18298893</comment>.<pub-id pub-id-type="pmid">18298893</pub-id>
</mixed-citation></ref><ref id="cit0003"><label>[3]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Boureux</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Vignal</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Faure</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Evolution of the rho family of ras-like GTPases in eukaryotes</article-title>. <source>Mol Biol Evol</source>. <year>2007</year>;<volume>24</volume>(<issue>1</issue>):<fpage>203</fpage>&#x02013;<lpage>216</lpage>. <comment>Epub 20061011</comment>. doi: <pub-id pub-id-type="doi">10.1093/molbev/msl145</pub-id>
<comment>PubMed PMID: 17035353; PubMed Central PMCID: PMCPMC2665304</comment>.<pub-id pub-id-type="pmid">17035353</pub-id>
</mixed-citation></ref><ref id="cit0004"><label>[4]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hodge</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Ridley</surname>
<given-names>AJ</given-names></string-name></person-group>. <article-title>Regulating rho GTPases and their regulators</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2016</year>;<volume>17</volume>(<issue>8</issue>):<fpage>496</fpage>&#x02013;<lpage>510</lpage>. <comment>Epub 20160615</comment>. doi: <pub-id pub-id-type="doi">10.1038/nrm.2016.67</pub-id>
<comment>PubMed PMID: 27301673</comment>.<pub-id pub-id-type="pmid">27301673</pub-id>
</mixed-citation></ref><ref id="cit0005"><label>[5]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jung</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Yoon</surname>
<given-names>SR</given-names></string-name>, <string-name><surname>Lim</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>Dysregulation of rho GTPases in human cancers</article-title>. <source>Cancers (Basel)</source>. <year>2020</year>;<volume>12</volume>(<issue>5</issue>). <comment>Epub 20200507</comment>. 1179. doi: <pub-id pub-id-type="doi">10.3390/cancers12051179</pub-id>
<comment>PubMed PMID: 32392742; PubMed Central PMCID: PMCPMC7281333</comment>.</mixed-citation></ref><ref id="cit0006"><label>[6]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qu</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Pan</surname>
<given-names>C</given-names></string-name>, <string-name><surname>He</surname>
<given-names>SM</given-names></string-name>, et al</person-group>. <article-title>The ras superfamily of small GTPases in non-neoplastic cerebral diseases</article-title>. <source>Front Mol Neurosci</source>. <year>2019</year>;<volume>12</volume>:<fpage>121</fpage>. <comment>Epub 20190521</comment>. doi: <pub-id pub-id-type="doi">10.3389/fnmol.2019.00121</pub-id>
<comment>PubMed PMID: 31213978; PubMed Central PMCID: PMCPMC6555388</comment>.<pub-id pub-id-type="pmid">31213978</pub-id>
</mixed-citation></ref><ref id="cit0007"><label>[7]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bustelo</surname>
<given-names>XR</given-names></string-name>, <string-name><surname>Sauzeau</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Berenjeno</surname>
<given-names>IM</given-names></string-name></person-group>. <article-title>GTP-binding proteins of the Rho/Rac family: regulation, effectors and functions in vivo</article-title>. <source>Bioessays</source>. <year>2007</year>;<volume>29</volume>(<issue>4</issue>):<fpage>356</fpage>&#x02013;<lpage>370</lpage>. doi: <pub-id pub-id-type="doi">10.1002/bies.20558</pub-id>
<comment>PubMed PMID: 17373658; PubMed Central PMCID: PMCPMC1971132</comment>.<pub-id pub-id-type="pmid">17373658</pub-id>
</mixed-citation></ref><ref id="cit0008"><label>[8]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kowluru</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Radhakrishnan</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Mohammad</surname>
<given-names>G</given-names></string-name></person-group>. <article-title>Regulation of Rac1 transcription by histone and DNA methylation in diabetic retinopathy</article-title>. <source>Sci Rep</source>. <year>2021</year>;<volume>11</volume>(<issue>1</issue>):<fpage>14097</fpage>. <comment>Epub 20210708</comment>. doi: <pub-id pub-id-type="doi">10.1038/s41598-021-93420-4</pub-id>
<comment>PubMed PMID: 34238980; PubMed Central PMCID: PMCPMC8266843</comment>.<pub-id pub-id-type="pmid">34238980</pub-id>
</mixed-citation></ref><ref id="cit0009"><label>[9]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Krauthammer</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kong</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Ha</surname>
<given-names>BH</given-names></string-name>, et al</person-group>. <article-title>Exome sequencing identifies recurrent somatic RAC1 mutations in melanoma</article-title>. <source>Nat Genet</source>. <year>2012</year>;<volume>44</volume>(<issue>9</issue>):<fpage>1006</fpage>&#x02013;<lpage>1014</lpage>. <comment>Epub 2012/07/31</comment>. doi: <pub-id pub-id-type="doi">10.1038/ng.2359</pub-id>
<comment>PubMed PMID: 22842228; PubMed Central PMCID: PMCPMC3432702</comment>.<pub-id pub-id-type="pmid">22842228</pub-id>
</mixed-citation></ref><ref id="cit0010"><label>[10]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fiegen</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Haeusler</surname>
<given-names>LC</given-names></string-name>, <string-name><surname>Blumenstein</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Alternative splicing of Rac1 generates Rac1b, a self-activating GTPase</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>(<issue>6</issue>):<fpage>4743</fpage>&#x02013;<lpage>4749</lpage>. <comment>Epub 20031118</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M310281200</pub-id>
<comment>PubMed PMID: 14625275</comment>.<pub-id pub-id-type="pmid">14625275</pub-id>
</mixed-citation></ref><ref id="cit0011"><label>[11]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jordan</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Braz&#x000c3;&#x000a3;o</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Boavida</surname>
<given-names>MG</given-names></string-name>, et al</person-group>. <article-title>Cloning of a novel human Rac1b splice variant with increased expression in colorectal tumors</article-title>. <source>Oncogene</source>. <year>1999</year>;<volume>18</volume>(<issue>48</issue>):<fpage>6835</fpage>&#x02013;<lpage>6839</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1203233</pub-id>
<comment>PubMed PMID: 10597294</comment>.<pub-id pub-id-type="pmid">10597294</pub-id>
</mixed-citation></ref><ref id="cit0012"><label>[12]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Senyuz</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Jang</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Nussinov</surname>
<given-names>R</given-names></string-name>, et al</person-group>. <article-title>Mechanistic differences of activation of Rac1(P29S) and Rac1(A159V)</article-title>. <source>J Phys Chem B</source>. <year>2021</year>;<volume>125</volume>(<issue>15</issue>):<fpage>3790</fpage>&#x02013;<lpage>3802</lpage>. <comment>Epub 20210413</comment>. doi: <pub-id pub-id-type="doi">10.1021/acs.jpcb.1c00883</pub-id>
<comment>PubMed PMID: 33848152; PubMed Central PMCID: PMCPMC8154616</comment>.<pub-id pub-id-type="pmid">33848152</pub-id>
</mixed-citation></ref><ref id="cit0013"><label>[13]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hirshberg</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Stockley</surname>
<given-names>RW</given-names></string-name>, <string-name><surname>Dodson</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>The crystal structure of human rac1, a member of the rho-family complexed with a GTP analogue</article-title>. <source>Nat Struct Mol Biol</source>. <year>1997</year>;<volume>4</volume>(<issue>2</issue>):<fpage>147</fpage>&#x02013;<lpage>152</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nsb0297-147</pub-id>
<comment>PubMed PMID: 9033596</comment>.</mixed-citation></ref><ref id="cit0014"><label>[14]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Didsbury</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Weber</surname>
<given-names>RF</given-names></string-name>, <string-name><surname>Bokoch</surname>
<given-names>GM</given-names></string-name>, et al</person-group>. <article-title>Rac, a novel ras-related family of proteins that are botulinum toxin substrates</article-title>. <source>J Biol Chem</source>. <year>1989</year>;<volume>264</volume>(<issue>28</issue>):<fpage>16378</fpage>&#x02013;<lpage>16382</lpage>. <comment>PubMed PMID: 2674130</comment>. doi: <pub-id pub-id-type="doi">10.1016/S0021-9258(19)84716-6</pub-id><pub-id pub-id-type="pmid">2674130</pub-id>
</mixed-citation></ref><ref id="cit0015"><label>[15]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Didsbury</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Uhing</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Snyderman</surname>
<given-names>R</given-names></string-name></person-group>. <article-title>Isoprenylation of the low molecular mass GTP-binding proteins rac 1 and rac 2: possible role in membrane localization</article-title>. <source>Biochem Biophys Res Commun</source>. <year>1990</year>;<volume>171</volume>(<issue>2</issue>):<fpage>804</fpage>&#x02013;<lpage>812</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0006-291x(90)91217-g</pub-id>
<comment>PubMed PMID: 2119580</comment>.<pub-id pub-id-type="pmid">2119580</pub-id>
</mixed-citation></ref><ref id="cit0016"><label>[16]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DerMardirossian</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Bokoch</surname>
<given-names>GM</given-names></string-name></person-group>. <article-title>Gdis: central regulatory molecules in rho GTPase activation</article-title>. <source>Trends Cell Biol</source>. <year>2005</year>;<volume>15</volume>(<issue>7</issue>):<fpage>356</fpage>&#x02013;<lpage>363</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.tcb.2005.05.001</pub-id>
<comment>PubMed PMID: 15921909</comment>.<pub-id pub-id-type="pmid">15921909</pub-id>
</mixed-citation></ref><ref id="cit0017"><label>[17]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dovas</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Couchman</surname>
<given-names>JR</given-names></string-name></person-group>. <article-title>RhoGDI: multiple functions in the regulation of rho family GTPase activities</article-title>. <source>Biochem J</source>. <year>2005</year>;<volume>390</volume>(<issue>Pt 1</issue>):<fpage>1</fpage>&#x02013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1042/BJ20050104</pub-id>
<comment>PubMed PMID: 16083425; PubMed Central PMCID: PMCPMC1184558</comment>.<pub-id pub-id-type="pmid">16083425</pub-id>
</mixed-citation></ref><ref id="cit0018"><label>[18]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>DerMardirossian</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Schnelzer</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Bokoch</surname>
<given-names>GM</given-names></string-name></person-group>. <article-title>Phosphorylation of RhoGDI by Pak1 mediates dissociation of Rac GTPase</article-title>. <source>Mol Cell</source>. <year>2004</year>;<volume>15</volume>(<issue>1</issue>):<fpage>117</fpage>&#x02013;<lpage>127</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.molcel.2004.05.019</pub-id>
<comment>PubMed PMID: 15225553</comment>.<pub-id pub-id-type="pmid">15225553</pub-id>
</mixed-citation></ref><ref id="cit0019"><label>[19]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vetter</surname>
<given-names>IR</given-names></string-name>, <string-name><surname>Wittinghofer</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>The guanine nucleotide-binding switch in three dimensions</article-title>. <source>Science</source>. <year>2001</year>;<volume>294</volume>(<issue>5545</issue>):<fpage>1299</fpage>&#x02013;<lpage>1304</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1062023</pub-id>
<comment>PubMed PMID: 11701921</comment>.<pub-id pub-id-type="pmid">11701921</pub-id>
</mixed-citation></ref><ref id="cit0020"><label>[20]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Grubisha</surname>
<given-names>MJ</given-names></string-name>, <string-name><surname>DeGiosio</surname>
<given-names>RA</given-names></string-name>, <string-name><surname>Wills</surname>
<given-names>ZP</given-names></string-name>, et al</person-group>. <article-title>Trio and Kalirin as unique enactors of Rho/Rac spatiotemporal precision</article-title>. <source>Cell Signal</source>. <year>2022</year>;<volume>98</volume>:<fpage>110416</fpage>. <comment>Epub 20220722</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.cellsig.2022.110416</pub-id>
<comment>PubMed PMID: 35872089</comment>.<pub-id pub-id-type="pmid">35872089</pub-id>
</mixed-citation></ref><ref id="cit0021"><label>[21]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Habets</surname>
<given-names>GG</given-names></string-name>, <string-name><surname>Scholtes</surname>
<given-names>EH</given-names></string-name>, <string-name><surname>Zuydgeest</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Identification of an invasion-inducing gene, tiam-1, that encodes a protein with homology to GDP-GTP exchangers for rho-like proteins</article-title>. <source>Cell</source>. <year>1994</year>;<volume>77</volume>(<issue>4</issue>):<fpage>537</fpage>&#x02013;<lpage>549</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0092-8674(94)90216-x</pub-id>
<comment>PubMed PMID: 7999144</comment>.<pub-id pub-id-type="pmid">7999144</pub-id>
</mixed-citation></ref><ref id="cit0022"><label>[22]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mertens</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Roovers</surname>
<given-names>RC</given-names></string-name>, <string-name><surname>Collard</surname>
<given-names>JG</given-names></string-name></person-group>. <article-title>Regulation of Tiam1-rac signalling</article-title>. <source>FEBS Lett</source>. <year>2003</year>;<volume>546</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>16</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0014-5793(03)00435-6</pub-id>
<comment>PubMed PMID: 12829230</comment>.<pub-id pub-id-type="pmid">12829230</pub-id>
</mixed-citation></ref><ref id="cit0023"><label>[23]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cooke</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Kreider-Letterman</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Baker</surname>
<given-names>MJ</given-names></string-name>, et al</person-group>. <article-title>FARP1, ARHGEF39, and TIAM2 are essential receptor tyrosine kinase effectors for Rac1-dependent cell motility in human lung adenocarcinoma</article-title>. <source>Cell Rep</source>. <year>2021</year>;<volume>37</volume>(<issue>5</issue>):<fpage>109905</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.celrep.2021.109905</pub-id>
<comment>PubMed PMID: 34731623; PubMed Central PMCID: PMCPMC8627373</comment>.<pub-id pub-id-type="pmid">34731623</pub-id>
</mixed-citation></ref><ref id="cit0024"><label>[24]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Charron</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Willert</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lipkowitz</surname>
<given-names>B</given-names></string-name>, et al</person-group>. <article-title>Two isoforms of the RAC-specific guanine nucleotide exchange factor TIAM2 act oppositely on transmission ratio distortion by the mouse t-haplotype</article-title>. <source>PLOS Genet</source>. <year>2019</year>;<volume>15</volume>(<issue>2</issue>):<fpage>e1007964</fpage>. <comment>Epub 20190228</comment>. doi: <pub-id pub-id-type="doi">10.1371/journal.pgen.1007964</pub-id>
<comment>PubMed PMID: 30817801; PubMed Central PMCID: PMCPMC6394906</comment>.<pub-id pub-id-type="pmid">30817801</pub-id>
</mixed-citation></ref><ref id="cit0025"><label>[25]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kiyokawa</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Hashimoto</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Kobayashi</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Activation of Rac1 by a crk SH3-binding protein, DOCK180</article-title>. <source>Genes Dev</source>. <year>1998</year>;<volume>12</volume>(<issue>21</issue>):<fpage>3331</fpage>&#x02013;<lpage>3336</lpage>. doi: <pub-id pub-id-type="doi">10.1101/gad.12.21.3331</pub-id>
<comment>PubMed PMID: 9808620; PubMed Central PMCID: PMCPMC317231</comment>.<pub-id pub-id-type="pmid">9808620</pub-id>
</mixed-citation></ref><ref id="cit0026"><label>[26]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Koubek</surname>
<given-names>EJ</given-names></string-name>, <string-name><surname>Santy</surname>
<given-names>LC</given-names></string-name></person-group>. <article-title>Actin up: an overview of the rac GEF Dock1/Dock180 and its role in cytoskeleton rearrangement</article-title>. <source>Cells</source>. <year>2022</year>;<volume>11</volume>(<issue>22</issue>). <comment>Epub 20221111</comment>. doi: <pub-id pub-id-type="doi">10.3390/cells11223565</pub-id>
<comment>PubMed PMID: 36428994; PubMed Central PMCID: PMCPMC9688060</comment>.</mixed-citation></ref><ref id="cit0027"><label>[27]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>ten Klooster</surname>
<given-names>JP</given-names></string-name>, <string-name><surname>Jaffer</surname>
<given-names>ZM</given-names></string-name>, <string-name><surname>Chernoff</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>Targeting and activation of Rac1 are mediated by the exchange factor beta-pix</article-title>. <source>J Cell Biol</source>. <year>2006</year>;<volume>172</volume>(<issue>5</issue>):<fpage>759</fpage>&#x02013;<lpage>769</lpage>. <comment>Epub 20060221</comment>. doi: <pub-id pub-id-type="doi">10.1083/jcb.200509096</pub-id>
<comment>PubMed PMID: 16492808; PubMed Central PMCID: PMCPMC2063707</comment>.<pub-id pub-id-type="pmid">16492808</pub-id>
</mixed-citation></ref><ref id="cit0028"><label>[28]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morales-Mantilla</surname>
<given-names>DE</given-names></string-name>, <string-name><surname>King</surname>
<given-names>KY</given-names></string-name></person-group>. <article-title>FGD5 marks a subpopulation of hematopoietic stem and progenitor cells that resist interferon-gamma-mediated differentiation</article-title>. <source>Exp Hematol</source>. <year>2022</year>;<volume>112&#x02013;113</volume>:<fpage>35</fpage>&#x02013;<lpage>43</lpage>. <comment>Epub 20220626</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.exphem.2022.06.001</pub-id>
<comment>PubMed PMID: 35768035</comment>.</mixed-citation></ref><ref id="cit0029"><label>[29]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barrows</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Schoenfeld</surname>
<given-names>SM</given-names></string-name>, <string-name><surname>Hodakoski</surname>
<given-names>C</given-names></string-name>, et al</person-group>. <article-title>p21-activated kinases (PAKs) mediate the phosphorylation of PREX2 protein to initiate feedback inhibition of Rac1 GTPase</article-title>. <source>J Biol Chem</source>. <year>2015</year>;<volume>290</volume>(<issue>48</issue>):<fpage>28915</fpage>&#x02013;<lpage>28931</lpage>. <comment>Epub 20151005</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M115.668244</pub-id>
<comment>PubMed PMID: 26438819; PubMed Central PMCID: PMCPMC4661405</comment>.<pub-id pub-id-type="pmid">26438819</pub-id>
</mixed-citation></ref><ref id="cit0030"><label>[30]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Manser</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Loo</surname>
<given-names>TH</given-names></string-name>, <string-name><surname>Koh</surname>
<given-names>CG</given-names></string-name>, et al</person-group>. <article-title>PAK kinases are directly coupled to the PIX family of nucleotide exchange factors</article-title>. <source>Mol Cell</source>. <year>1998</year>;<volume>1</volume>(<issue>2</issue>):<fpage>183</fpage>&#x02013;<lpage>192</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1097-2765(00)80019-2</pub-id>
<comment>PubMed PMID: 9659915</comment>.<pub-id pub-id-type="pmid">9659915</pub-id>
</mixed-citation></ref><ref id="cit0031"><label>[31]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shin</surname>
<given-names>EY</given-names></string-name>, <string-name><surname>Woo</surname>
<given-names>KN</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>CS</given-names></string-name>, et al</person-group>. <article-title>Basic fibroblast growth factor stimulates activation of Rac1 through a p85 betaPIX phosphorylation-dependent pathway</article-title>. <source>J Biol Chem</source>. <year>2004</year>;<volume>279</volume>(<issue>3</issue>):<fpage>1994</fpage>&#x02013;<lpage>2004</lpage>. <comment>Epub 20031013</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M307330200</pub-id>
<comment>PubMed PMID: 14557270</comment>.<pub-id pub-id-type="pmid">14557270</pub-id>
</mixed-citation></ref><ref id="cit0032"><label>[32]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Park</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Guo</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Negre</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>Fgd5 is a Rac1-specific rho GEF that is selectively inhibited by aurintricarboxylic acid</article-title>. <source>Small GTPases</source>. <year>2021</year>;<volume>12</volume>(<issue>2</issue>):<fpage>147</fpage>&#x02013;<lpage>160</lpage>. <comment>Epub 20191010</comment>. doi: <pub-id pub-id-type="doi">10.1080/21541248.2019.1674765</pub-id>
<comment>PubMed PMID: 31601145; PubMed Central PMCID: PMCPMC7849785</comment>.<pub-id pub-id-type="pmid">31601145</pub-id>
</mixed-citation></ref><ref id="cit0033"><label>[33]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Abiko</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Fujiwara</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ohashi</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Rho guanine nucleotide exchange factors involved in cyclic-stretch-induced reorientation of vascular endothelial cells</article-title>. <source>J Cell Sci</source>. <year>2015</year>;<volume>128</volume>(<issue>9</issue>):<fpage>1683</fpage>&#x02013;<lpage>1695</lpage>. <comment>Epub 20150320</comment>. doi: <pub-id pub-id-type="doi">10.1242/jcs.157503</pub-id>
<comment>PubMed PMID: 25795300</comment>.<pub-id pub-id-type="pmid">25795300</pub-id>
</mixed-citation></ref><ref id="cit0034"><label>[34]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reinhard</surname>
<given-names>NR</given-names></string-name>, <string-name><surname>Van Der Niet</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Chertkova</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Identification of guanine nucleotide exchange factors that increase Cdc42 activity in primary human endothelial cells</article-title>. <source>Small GTPases</source>. <year>2021</year>;<volume>12</volume>(<issue>3</issue>):<fpage>226</fpage>&#x02013;<lpage>240</lpage>. <comment>Epub 20190830</comment>. doi: <pub-id pub-id-type="doi">10.1080/21541248.2019.1658509</pub-id>
<comment>PubMed PMID: 31469028; PubMed Central PMCID: PMCPMC7939571</comment>.<pub-id pub-id-type="pmid">31469028</pub-id>
</mixed-citation></ref><ref id="cit0035"><label>[35]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Nguyen</surname>
<given-names>TT</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>WS</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>BO</given-names></string-name>, et al</person-group>. <article-title>PLEKHG3 enhances polarized cell migration by activating actin filaments at the cell front</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2016</year>;<volume>113</volume>(<issue>36</issue>):<fpage>10091</fpage>&#x02013;<lpage>10096</lpage>. <comment>Epub 20160823</comment>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1604720113</pub-id>
<comment>PubMed PMID: 27555588; PubMed Central PMCID: PMCPMC5018766</comment>.<pub-id pub-id-type="pmid">27555588</pub-id>
</mixed-citation></ref><ref id="cit0036"><label>[36]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bourbia</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Chandler</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Codner</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>The guanine nucleotide exchange factor, Spata13, influences social behaviour and nocturnal activity</article-title>. <source>Mamm Genome</source>. <year>2019</year>;<volume>30</volume>(<issue>3&#x02013;4</issue>):<fpage>54</fpage>&#x02013;<lpage>62</lpage>. <comment>Epub 20190424</comment>. doi: <pub-id pub-id-type="doi">10.1007/s00335-019-09800-9</pub-id>
<comment>PubMed PMID: 31020388; PubMed Central PMCID: PMCPMC6491400</comment>.<pub-id pub-id-type="pmid">31020388</pub-id>
</mixed-citation></ref><ref id="cit0037"><label>[37]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Itoh</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Kiyokawa</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Aoki</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Phosphorylation and activation of the Rac1 and Cdc42 GEF asef in A431 cells stimulated by EGF</article-title>. <source>J Cell Sci</source>. <year>2008</year>;<volume>121</volume>(<issue>Pt 16</issue>):<fpage>2635</fpage>&#x02013;<lpage>2642</lpage>. <comment>Epub 20080724</comment>. doi: <pub-id pub-id-type="doi">10.1242/jcs.028647</pub-id>
<comment>PubMed PMID: 18653540</comment>.<pub-id pub-id-type="pmid">18653540</pub-id>
</mixed-citation></ref><ref id="cit0038"><label>[38]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Thompson</surname>
<given-names>AP</given-names></string-name>, <string-name><surname>Bitsina</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Gray</surname>
<given-names>JL</given-names></string-name>, et al</person-group>. <article-title>RHO to the DOCK for GDP disembarking: structural insights into the DOCK GTPase nucleotide exchange factors</article-title>. <source>J Biol Chem</source>. <year>2021</year>;<volume>296</volume>:<fpage>100521</fpage>. <comment>Epub 20210305</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.jbc.2021.100521</pub-id>
<comment>PubMed PMID: 33684443; PubMed Central PMCID: PMCPMC8063744</comment>.<pub-id pub-id-type="pmid">33684443</pub-id>
</mixed-citation></ref><ref id="cit0039"><label>[39]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bustelo</surname>
<given-names>XR</given-names></string-name></person-group>. <article-title>Regulatory and signaling properties of the Vav family</article-title>. <source>Mol Cell Biol</source>. <year>2000</year>;<volume>20</volume>(<issue>5</issue>):<fpage>1461</fpage>&#x02013;<lpage>1477</lpage>. doi: <pub-id pub-id-type="doi">10.1128/MCB.20.5.1461-1477.2000</pub-id>
<comment>PubMed PMID: 10669724; PubMed Central PMCID: PMCPMC85310</comment>.<pub-id pub-id-type="pmid">10669724</pub-id>
</mixed-citation></ref><ref id="cit0040"><label>[40]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Movilla</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Dosil</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>How vav proteins discriminate the GTPases Rac1 and RhoA from Cdc42</article-title>. <source>Oncogene</source>. <year>2001</year>;<volume>20</volume>(<issue>56</issue>):<fpage>8057</fpage>&#x02013;<lpage>8065</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1205000</pub-id>
<comment>PubMed PMID: 11781818</comment>.<pub-id pub-id-type="pmid">11781818</pub-id>
</mixed-citation></ref><ref id="cit0041"><label>[41]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kim</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>D</given-names></string-name></person-group>. <article-title>Emerging roles of ephexins in physiology and disease</article-title>. <source>Cells</source>. <year>2019</year>;<volume>8</volume>(<issue>2</issue>). <comment>Epub 20190124</comment>. <fpage>87</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells8020087</pub-id>
<comment>PubMed PMID: 30682817; PubMed Central PMCID: PMCPMC6406967</comment>.<pub-id pub-id-type="pmid">30682817</pub-id>
</mixed-citation></ref><ref id="cit0042"><label>[42]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hiramoto-Yamaki</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Takeuchi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ueda</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Ephexin4 and EphA2 mediate cell migration through a RhoG-dependent mechanism</article-title>. <source>J Cell Biol</source>. <year>2010</year>;<volume>190</volume>(<issue>3</issue>):<fpage>461</fpage>&#x02013;<lpage>477</lpage>. <comment>Epub 20100802</comment>. doi: <pub-id pub-id-type="doi">10.1083/jcb.201005141</pub-id>
<comment>PubMed PMID: 20679435; PubMed Central PMCID: PMCPMC2922637</comment>.<pub-id pub-id-type="pmid">20679435</pub-id>
</mixed-citation></ref><ref id="cit0043"><label>[43]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Park</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Kim</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>Arhgef16, a novel Elmo1 binding partner, promotes clearance of apoptotic cells via RhoG-dependent Rac1 activation</article-title>. <source>Biochim Biophys Acta</source>. <year>2014</year>;<volume>1843</volume>(<issue>11</issue>):<fpage>2438</fpage>&#x02013;<lpage>2447</lpage>. <comment>Epub 20140723</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.bbamcr.2014.07.006</pub-id>
<comment>PubMed PMID: 25063526</comment>.<pub-id pub-id-type="pmid">25063526</pub-id>
</mixed-citation></ref><ref id="cit0044"><label>[44]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>Z</given-names></string-name>, et al</person-group>. <article-title>DEF6(differentially exprehomolog) exacerbates pathological cardiac hypertrophy via RAC1</article-title>. <source>Cell Death Dis</source>. <year>2023</year>;<volume>14</volume>(<issue>7</issue>):<fpage>483</fpage>. <comment>Epub 20230731</comment>. doi: <pub-id pub-id-type="doi">10.1038/s41419-023-05948-0</pub-id>
<comment>PubMed PMID: 37524688; PubMed Central PMCID: PMCPMC10390462</comment>.<pub-id pub-id-type="pmid">37524688</pub-id>
</mixed-citation></ref><ref id="cit0045"><label>[45]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Oka</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ihara</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Fukui</surname>
<given-names>Y</given-names></string-name></person-group>. <article-title>Cooperation of DEF6 with activated rac in regulating cell morphology</article-title>. <source>J Biol Chem</source>. <year>2007</year>;<volume>282</volume>(<issue>3</issue>):<fpage>2011</fpage>&#x02013;<lpage>2018</lpage>. <comment>Epub 20061122</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M605153200</pub-id>
<comment>PubMed PMID: 17121847</comment>.<pub-id pub-id-type="pmid">17121847</pub-id>
</mixed-citation></ref><ref id="cit0046"><label>[46]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mavrakis</surname>
<given-names>KJ</given-names></string-name>, <string-name><surname>McKinlay</surname>
<given-names>KJ</given-names></string-name>, <string-name><surname>Jones</surname>
<given-names>P</given-names></string-name>, et al</person-group>. <article-title>DEF6, a novel PH-DH-like domain protein, is an upstream activator of the rho GTPases Rac1, Cdc42, and RhoA</article-title>. <source>Exp Cell Res</source>. <year>2004</year>;<volume>294</volume>(<issue>2</issue>):<fpage>335</fpage>&#x02013;<lpage>344</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.yexcr.2003.12.004</pub-id>
<comment>PubMed PMID: 15023524</comment>.<pub-id pub-id-type="pmid">15023524</pub-id>
</mixed-citation></ref><ref id="cit0047"><label>[47]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Barrio-Real</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Benedetti</surname>
<given-names>LG</given-names></string-name>, <string-name><surname>Engel</surname>
<given-names>N</given-names></string-name>, et al</person-group>. <article-title>Subtype-specific overexpression of the rac-GEF P-REX1 in breast cancer is associated with promoter hypomethylation</article-title>. <source>Breast Cancer Res</source>. <year>2014</year>;<volume>16</volume>(<issue>5</issue>):<fpage>441</fpage>. <comment>Epub 20140924</comment>. doi: <pub-id pub-id-type="doi">10.1186/s13058-014-0441-7</pub-id>
<comment>PubMed PMID: 25248717; PubMed Central PMCID: PMCPMC4303123</comment>.<pub-id pub-id-type="pmid">25248717</pub-id>
</mixed-citation></ref><ref id="cit0048"><label>[48]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hampson</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Tsonou</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Baker</surname>
<given-names>MJ</given-names></string-name>, et al</person-group>. <article-title>P-Rex1 controls sphingosine 1-phosphate receptor signalling, morphology, and cell-cycle progression in neuronal cells</article-title>. <source>Cells</source>. <year>2021</year>;<volume>10</volume>(<issue>9</issue>). <comment>Epub 20210918</comment>. doi: <pub-id pub-id-type="doi">10.3390/cells10092474</pub-id>
<comment>PubMed PMID: 34572121; PubMed Central PMCID: PMCPMC8469755</comment>.</mixed-citation></ref><ref id="cit0049"><label>[49]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosenfeldt</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Vazquez-Prado</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gutkind</surname>
<given-names>JS</given-names></string-name></person-group>. <article-title>P-REX2, a novel PI-3-kinase sensitive rac exchange factor</article-title>. <source>FEBS Lett</source>. <year>2004</year>;<volume>572</volume>(<issue>1&#x02013;3</issue>):<fpage>167</fpage>&#x02013;<lpage>171</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.febslet.2004.06.097</pub-id>
<comment>PubMed PMID: 15304342</comment>.<pub-id pub-id-type="pmid">15304342</pub-id>
</mixed-citation></ref><ref id="cit0050"><label>[50]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cash</surname>
<given-names>JN</given-names></string-name>, <string-name><surname>Davis</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Tesmer</surname>
<given-names>JJG</given-names></string-name></person-group>. <article-title>Structural and biochemical characterization of the catalytic core of the metastatic factor P-Rex1 and Its regulation by PtdIns(3,4,5)P3</article-title>. <source>Structure</source>. <year>2016</year>;<volume>24</volume>(<issue>5</issue>):<fpage>730</fpage>&#x02013;<lpage>740</lpage>. <comment>Epub 20160414</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.str.2016.02.022</pub-id>
<comment>PubMed PMID: 27150042; PubMed Central PMCID: PMCPMC4860252</comment>.<pub-id pub-id-type="pmid">27150042</pub-id>
</mixed-citation></ref><ref id="cit0051"><label>[51]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Damoulakis</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Gambardella</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Rossman</surname>
<given-names>KL</given-names></string-name>, et al</person-group>. <article-title>P-Rex1 directly activates RhoG to regulate GPCR-driven rac signalling and actin polarity in neutrophils</article-title>. <source>J Cell Sci</source>. <year>2014</year>;<volume>127</volume>(<issue>Pt 11</issue>):<fpage>2589</fpage>&#x02013;<lpage>2600</lpage>. <comment>Epub 20140321</comment>. doi: <pub-id pub-id-type="doi">10.1242/jcs.153049</pub-id>
<comment>PubMed PMID: 24659802</comment>.<pub-id pub-id-type="pmid">24659802</pub-id>
</mixed-citation></ref><ref id="cit0052"><label>[52]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baird</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>Q</given-names></string-name>, <string-name><surname>Cerione</surname>
<given-names>RA</given-names></string-name></person-group>. <article-title>The cool-2/alpha-pix protein mediates a Cdc42-rac signaling cascade</article-title>. <source>Curr Biol</source>. <year>2005</year>;<volume>15</volume>(<issue>1</issue>):<fpage>1</fpage>&#x02013;<lpage>10</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cub.2004.12.040</pub-id>
<comment>PubMed PMID: 15649357</comment>.<pub-id pub-id-type="pmid">15649357</pub-id>
</mixed-citation></ref><ref id="cit0053"><label>[53]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hirano</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Shinsato</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Tanabe</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>FARP1 boosts CDC42 activity from integrin alphavbeta5 signaling and correlates with poor prognosis of advanced gastric cancer</article-title>. <source>Oncogenesis</source>. <year>2020</year>;<volume>9</volume>(<issue>2</issue>):<fpage>13</fpage>. <comment>Epub 20200206</comment>. doi: <pub-id pub-id-type="doi">10.1038/s41389-020-0190-7</pub-id>
<comment>PubMed PMID: 32029704; PubMed Central PMCID: PMCPMC7005035</comment>.<pub-id pub-id-type="pmid">32029704</pub-id>
</mixed-citation></ref><ref id="cit0054"><label>[54]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fan</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Yan</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Pellegrin</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>The rif GTPase regulates cytoskeletal signaling from plexinA4 to promote neurite retraction</article-title>. <source>Neurosci Lett</source>. <year>2015</year>;<volume>590</volume>:<fpage>178</fpage>&#x02013;<lpage>183</lpage>. <comment>Epub 20150207</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.neulet.2015.02.010</pub-id>
<comment>PubMed PMID: 25668492</comment>.<pub-id pub-id-type="pmid">25668492</pub-id>
</mixed-citation></ref><ref id="cit0055"><label>[55]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Guo</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Stafford</surname>
<given-names>LJ</given-names></string-name>, <string-name><surname>Bryan</surname>
<given-names>B</given-names></string-name>, et al</person-group>. <article-title>A Rac/Cdc42-specific exchange factor, GEFT, induces cell proliferation, transformation, and migration</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>(<issue>15</issue>):<fpage>13207</fpage>&#x02013;<lpage>13215</lpage>. <comment>Epub 20030123</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M208896200</pub-id>
<comment>PubMed PMID: 12547822</comment>.<pub-id pub-id-type="pmid">12547822</pub-id>
</mixed-citation></ref><ref id="cit0056"><label>[56]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Innocenti</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Zippel</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Brambilla</surname>
<given-names>R</given-names></string-name>, et al</person-group>. <article-title>CDC25(Mm)/Ras-GRF1 regulates both ras and rac signaling pathways</article-title>. <source>FEBS Lett</source>. <year>1999</year>;<volume>460</volume>(<issue>2</issue>):<fpage>357</fpage>&#x02013;<lpage>362</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0014-5793(99)01374-5</pub-id>
<comment>PubMed PMID: 10544264</comment>.<pub-id pub-id-type="pmid">10544264</pub-id>
</mixed-citation></ref><ref id="cit0057"><label>[57]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kiyono</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Satoh</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Kaziro</surname>
<given-names>Y</given-names></string-name></person-group>. <article-title>G protein beta gamma subunit-dependent Rac-guanine nucleotide exchange activity of ras-GRF1/CDC25(Mm)</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>1999</year>;<volume>96</volume>(<issue>9</issue>):<fpage>4826</fpage>&#x02013;<lpage>4831</lpage>. doi: <pub-id pub-id-type="doi">10.1073/pnas.96.9.4826</pub-id>
<comment>PubMed PMID: 10220378; PubMed Central PMCID: PMCPMC21776</comment>.<pub-id pub-id-type="pmid">10220378</pub-id>
</mixed-citation></ref><ref id="cit0058"><label>[58]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schwechter</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Rosenmund</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Tolias</surname>
<given-names>KF</given-names></string-name></person-group>. <article-title>RasGRF2 rac-GEF activity couples NMDA receptor calcium flux to enhanced synaptic transmission</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2013</year>;<volume>110</volume>(<issue>35</issue>):<fpage>14462</fpage>&#x02013;<lpage>14467</lpage>. <comment>Epub 20130812</comment>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1304340110</pub-id>
<comment>PubMed PMID: 23940355; PubMed Central PMCID: PMCPMC3761609</comment>.<pub-id pub-id-type="pmid">23940355</pub-id>
</mixed-citation></ref><ref id="cit0059"><label>[59]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olevska</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Spanagel</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bernardi</surname>
<given-names>RE</given-names></string-name></person-group>. <article-title>Impaired contextual fear conditioning in RasGRF2 mutant mice is likely ras-ERK-dependent</article-title>. <source>Neurobiol Learn Mem</source>. <year>2021</year>;<volume>181</volume>:<fpage>107435</fpage>. <comment>Epub 20210406</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.nlm.2021.107435</pub-id>
<comment>PubMed PMID: 33831510</comment>.<pub-id pub-id-type="pmid">33831510</pub-id>
</mixed-citation></ref><ref id="cit0060"><label>[60]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Baltanas</surname>
<given-names>FC</given-names></string-name>, <string-name><surname>Zarich</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Rojas-Cabaneros</surname>
<given-names>JM</given-names></string-name>, et al</person-group>. <article-title>SOS GEFs in health and disease</article-title>. <source>Biochim Biophys Acta Rev Cancer</source>. <year>2020</year>;<volume>1874</volume>(<issue>2</issue>):<fpage>188445</fpage>. <comment>Epub 20201006</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.bbcan.2020.188445</pub-id>
<comment>PubMed PMID: 33035641</comment>.<pub-id pub-id-type="pmid">33035641</pub-id>
</mixed-citation></ref><ref id="cit0061"><label>[61]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rojas</surname>
<given-names>JM</given-names></string-name>, <string-name><surname>Oliva</surname>
<given-names>JL</given-names></string-name>, <string-name><surname>Santos</surname>
<given-names>E</given-names></string-name></person-group>. <article-title>Mammalian son of sevenless guanine nucleotide exchange factors: old concepts and new perspectives</article-title>. <source>Genes Cancer</source>. <year>2011</year>;<volume>2</volume>(<issue>3</issue>):<fpage>298</fpage>&#x02013;<lpage>305</lpage>. doi: <pub-id pub-id-type="doi">10.1177/1947601911408078</pub-id>
<comment>PubMed PMID: 21779500; PubMed Central PMCID: PMCPMC3128634</comment>.<pub-id pub-id-type="pmid">21779500</pub-id>
</mixed-citation></ref><ref id="cit0062"><label>[62]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rossman</surname>
<given-names>KL</given-names></string-name>, <string-name><surname>Der</surname>
<given-names>CJ</given-names></string-name>, <string-name><surname>Sondek</surname>
<given-names>J</given-names></string-name></person-group>. <article-title>GEF means go: turning on RHO GTPases with guanine nucleotide-exchange factors</article-title>. <source>Nat Rev Mol Cell Biol</source>. <year>2005</year>;<volume>6</volume>(<issue>2</issue>):<fpage>167</fpage>&#x02013;<lpage>180</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrm1587</pub-id><pub-id pub-id-type="pmid">15688002</pub-id>
</mixed-citation></ref><ref id="cit0063"><label>[63]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Acuner</surname>
<given-names>SE</given-names></string-name>, <string-name><surname>Sumbul</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Torun</surname>
<given-names>H</given-names></string-name>, et al</person-group>. <article-title>Oncogenic mutations on Rac1 affect global intrinsic dynamics underlying GTP and PAK1 binding</article-title>. <source>Biophys J</source>. <year>2021</year>;<volume>120</volume>(<issue>5</issue>):<fpage>866</fpage>&#x02013;<lpage>876</lpage>. <comment>Epub 20210128</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.bpj.2021.01.016</pub-id>
<comment>PubMed PMID: 33515600; PubMed Central PMCID: PMCPMC8008323</comment>.<pub-id pub-id-type="pmid">33515600</pub-id>
</mixed-citation></ref><ref id="cit0064"><label>[64]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Maldonado</surname>
<given-names>MDM</given-names></string-name>, <string-name><surname>Medina</surname>
<given-names>JI</given-names></string-name>, <string-name><surname>Velazquez</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Targeting rac and Cdc42 GEFs in metastatic cancer</article-title>. <source>Front Cell Dev Biol</source>. <year>2020</year>;<volume>8</volume>:<fpage>201</fpage>. <comment>Epub 20200408</comment>. doi: <pub-id pub-id-type="doi">10.3389/fcell.2020.00201</pub-id>
<comment>PubMed PMID: 32322580; PubMed Central PMCID: PMCPMC7156542</comment>.<pub-id pub-id-type="pmid">32322580</pub-id>
</mixed-citation></ref><ref id="cit0065"><label>[65]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Warner</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Wilson</surname>
<given-names>BJ</given-names></string-name>, <string-name><surname>Caswell</surname>
<given-names>PT</given-names></string-name></person-group>. <article-title>Control of adhesion and protrusion in cell migration by rho GTPases</article-title>. <source>Curr Opin Cell Biol</source>. <year>2019</year>;<volume>56</volume>:<fpage>64</fpage>&#x02013;<lpage>70</lpage>. <comment>Epub 20181003</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.ceb.2018.09.003</pub-id>
<comment>PubMed PMID: 30292078; PubMed Central PMCID: PMCPMC6368645</comment>.<pub-id pub-id-type="pmid">30292078</pub-id>
</mixed-citation></ref><ref id="cit0066"><label>[66]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Parri</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Chiarugi</surname>
<given-names>P</given-names></string-name></person-group>. <article-title>Rac and rho GTPases in cancer cell motility control</article-title>. <source>Cell Commun Signal</source>. <year>2010</year>;<volume>8</volume>(<issue>1</issue>):<fpage>23</fpage>. <comment>Epub 20100907</comment>. doi: <pub-id pub-id-type="doi">10.1186/1478-811X-8-23</pub-id>
<comment>PubMed PMID: 20822528; PubMed Central PMCID: PMCPMC2941746</comment>.<pub-id pub-id-type="pmid">20822528</pub-id>
</mixed-citation></ref><ref id="cit0067"><label>[67]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jamieson</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Lui</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Brocardo</surname>
<given-names>MG</given-names></string-name>, et al</person-group>. <article-title>Rac1 augments wnt signaling by stimulating beta-catenin-lymphoid enhancer factor-1 complex assembly independent of beta-catenin nuclear import</article-title>. <source>J Cell Sci</source>. <year>2015</year>;<volume>128</volume>(<issue>21</issue>):<fpage>3933</fpage>&#x02013;<lpage>3946</lpage>. <comment>Epub 20150924</comment>. doi: <pub-id pub-id-type="doi">10.1242/jcs.167742</pub-id>
<comment>PubMed PMID: 26403202; PubMed Central PMCID: PMCPMC4657330</comment>.<pub-id pub-id-type="pmid">26403202</pub-id>
</mixed-citation></ref><ref id="cit0068"><label>[68]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Kurdi</surname>
<given-names>AT</given-names></string-name>, <string-name><surname>Bassil</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Olah</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Tiam1/Rac1 complex controls Il17a transcription and autoimmunity</article-title>. <source>Nat Commun</source>. <year>2016</year>;<volume>7</volume>(<issue>1</issue>):<fpage>13048</fpage>. <comment>Epub 20161011</comment>. doi: <pub-id pub-id-type="doi">10.1038/ncomms13048</pub-id>
<comment>PubMed PMID: 27725632; PubMed Central PMCID: PMCPMC5062600</comment>.<pub-id pub-id-type="pmid">27725632</pub-id>
</mixed-citation></ref><ref id="cit0069"><label>[69]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Buongiorno</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Pethe</surname>
<given-names>VV</given-names></string-name>, <string-name><surname>Charames</surname>
<given-names>GS</given-names></string-name>, et al</person-group>. <article-title>Rac1 GTPase and the Rac1 exchange factor Tiam1 associate with Wnt-responsive promoters to enhance beta-catenin/TCF-dependent transcription in colorectal cancer cells</article-title>. <source>Mol Cancer</source>. <year>2008</year>;<volume>7</volume>(<issue>1</issue>):<fpage>73</fpage>. <comment>Epub 20080930</comment>. doi: <pub-id pub-id-type="doi">10.1186/1476-4598-7-73</pub-id>
<comment>PubMed PMID: 18826597; PubMed Central PMCID: PMCPMC2565678</comment>.<pub-id pub-id-type="pmid">18826597</pub-id>
</mixed-citation></ref><ref id="cit0070"><label>[70]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hinde</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Yokomori</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Gaus</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Fluctuation-based imaging of nuclear Rac1 activation by protein oligomerisation</article-title>. <source>Sci Rep</source>. <year>2014</year>;<volume>4</volume>(<issue>1</issue>):<fpage>4219</fpage>. <comment>Epub 20140227</comment>. doi: <pub-id pub-id-type="doi">10.1038/srep04219</pub-id>
<comment>PubMed PMID: 24573109; PubMed Central PMCID: PMCPMC3936235</comment>.<pub-id pub-id-type="pmid">24573109</pub-id>
</mixed-citation></ref><ref id="cit0071"><label>[71]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Michaelson</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Abidi</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Guardavaccaro</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Rac1 accumulates in the nucleus during the G2 phase of the cell cycle and promotes cell division</article-title>. <source>J Cell Biol</source>. <year>2008</year>;<volume>181</volume>(<issue>3</issue>):<fpage>485</fpage>&#x02013;<lpage>496</lpage>. <comment>Epub 20080428</comment>. doi: <pub-id pub-id-type="doi">10.1083/jcb.200801047</pub-id>
<comment>PubMed PMID: 18443222; PubMed Central PMCID: PMCPMC2364699</comment>.<pub-id pub-id-type="pmid">18443222</pub-id>
</mixed-citation></ref><ref id="cit0072"><label>[72]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bustelo</surname>
<given-names>XR</given-names></string-name>, <string-name><surname>Ojeda</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Barreira</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Rac-ing to the plasma membrane: the long and complex work commute of Rac1 during cell signaling</article-title>. <source>Small GTPases</source>. <year>2012</year>;<volume>3</volume>(<issue>1</issue>):<fpage>60</fpage>&#x02013;<lpage>66</lpage>. doi: <pub-id pub-id-type="doi">10.4161/sgtp.19111</pub-id>
<comment>PubMed PMID: 22714419; PubMed Central PMCID: PMCPMC3398920</comment>.<pub-id pub-id-type="pmid">22714419</pub-id>
</mixed-citation></ref><ref id="cit0073"><label>[73]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Navarro-Lerida</surname>
<given-names>I</given-names></string-name>, <string-name><surname>Pellinen</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Sanchez</surname>
<given-names>SA</given-names></string-name>, et al</person-group>. <article-title>Rac1 nucleocytoplasmic shuttling drives nuclear shape changes and tumor invasion</article-title>. <source>Dev Cell</source>. <year>2015</year>;<volume>32</volume>(<issue>3</issue>):<fpage>318</fpage>&#x02013;<lpage>334</lpage>. <comment>Epub 20150129</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.devcel.2014.12.019</pub-id>
<comment>PubMed PMID: 25640224</comment>.<pub-id pub-id-type="pmid">25640224</pub-id>
</mixed-citation></ref><ref id="cit0074"><label>[74]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sun</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Gaidosh</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>RAC1 plays an essential role in estrogen receptor alpha function in breast cancer cells</article-title>. <source>Oncogene</source>. <year>2021</year>;<volume>40</volume>(<issue>40</issue>):<fpage>5950</fpage>&#x02013;<lpage>5962</lpage>. <comment>Epub 20210809</comment>. doi: <pub-id pub-id-type="doi">10.1038/s41388-021-01985-1</pub-id>
<comment>PubMed PMID: 34373577; PubMed Central PMCID: PMCPMC8497275</comment>.<pub-id pub-id-type="pmid">34373577</pub-id>
</mixed-citation></ref><ref id="cit0075"><label>[75]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Rosenblatt</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Garcia</surname>
<given-names>MI</given-names></string-name>, <string-name><surname>Lyons</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Inhibition of the rho GTPase, Rac1, decreases estrogen receptor levels and is a novel therapeutic strategy in breast cancer</article-title>. <source>Endocr Relat Cancer</source>. <year>2011</year>;<volume>18</volume>(<issue>2</issue>):<fpage>207</fpage>&#x02013;<lpage>219</lpage>. <comment>Epub 20110223</comment>. doi: <pub-id pub-id-type="doi">10.1677/ERC-10-0049</pub-id>
<comment>PubMed PMID: 21118977; PubMed Central PMCID: PMCPMC3644524</comment>.<pub-id pub-id-type="pmid">21118977</pub-id>
</mixed-citation></ref><ref id="cit0076"><label>[76]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uhlen</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Fagerberg</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Hallstrom</surname>
<given-names>BM</given-names></string-name>, et al</person-group>. <article-title>Proteomics. Tissue-based map of the human proteome</article-title>. <source>Science</source>. <year>2015</year>;<volume>347</volume>(<issue>6220</issue>):<fpage>1260419</fpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1260419</pub-id>
<comment>PubMed PMID: 25613900</comment>.<pub-id pub-id-type="pmid">25613900</pub-id>
</mixed-citation></ref><ref id="cit0077"><label>[77]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Olson</surname>
<given-names>MF</given-names></string-name>, <string-name><surname>Ashworth</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Hall</surname>
<given-names>A</given-names></string-name></person-group>. <article-title>An essential role for rho, rac, and Cdc42 GTPases in cell cycle progression through G1</article-title>. <source>Science</source>. <year>1995</year>;<volume>269</volume>(<issue>5228</issue>):<fpage>1270</fpage>&#x02013;<lpage>1272</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.7652575</pub-id>
<comment>PubMed PMID: 7652575</comment>.<pub-id pub-id-type="pmid">7652575</pub-id>
</mixed-citation></ref><ref id="cit0078"><label>[78]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Gu</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>RAC1 serves as a prognostic factor and correlated with immune infiltration in liver hepatocellular carcinoma</article-title>. <source>J Cancer Res Clin Oncol</source>. <year>2024</year>;<volume>150</volume>(<issue>9</issue>):<fpage>418</fpage>. <comment>Epub 20240912</comment>. doi: <pub-id pub-id-type="doi">10.1007/s00432-024-05933-w</pub-id>
<comment>PubMed PMID: 39264423; PubMed Central PMCID: PMCPMC11393158</comment>.<pub-id pub-id-type="pmid">39264423</pub-id>
</mixed-citation></ref><ref id="cit0079"><label>[79]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Gu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Filippi</surname>
<given-names>MD</given-names></string-name>, <string-name><surname>Cancelas</surname>
<given-names>JA</given-names></string-name>, et al</person-group>. <article-title>Hematopoietic cell regulation by Rac1 and Rac2 guanosine triphosphatases</article-title>. <source>Science</source>. <year>2003</year>;<volume>302</volume>(<issue>5644</issue>):<fpage>445</fpage>&#x02013;<lpage>449</lpage>. doi: <pub-id pub-id-type="doi">10.1126/science.1088485</pub-id>
<comment>PubMed PMID: 14564009</comment>.<pub-id pub-id-type="pmid">14564009</pub-id>
</mixed-citation></ref><ref id="cit0080"><label>[80]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sanz-Moreno</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Gadea</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ahn</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>Rac activation and inactivation control plasticity of tumor cell movement</article-title>. <source>Cell</source>. <year>2008</year>;<volume>135</volume>(<issue>3</issue>):<fpage>510</fpage>&#x02013;<lpage>523</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2008.09.043</pub-id>
<comment>PubMed PMID: 18984162</comment>.<pub-id pub-id-type="pmid">18984162</pub-id>
</mixed-citation></ref><ref id="cit0081"><label>[81]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sylow</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Moller</surname>
<given-names>LL</given-names></string-name>, <string-name><surname>Kleinert</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Stretch-stimulated glucose transport in skeletal muscle is regulated by Rac1</article-title>. <source>J Physiol</source>. <year>2015</year>;<volume>593</volume>(<issue>3</issue>):<fpage>645</fpage>&#x02013;<lpage>656</lpage>. <comment>Epub 20150115</comment>. doi: <pub-id pub-id-type="doi">10.1113/jphysiol.2014.284281</pub-id>
<comment>PubMed PMID: 25416624; PubMed Central PMCID: PMCPMC4324711</comment>.<pub-id pub-id-type="pmid">25416624</pub-id>
</mixed-citation></ref><ref id="cit0082"><label>[82]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sylow</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Nielsen</surname>
<given-names>IL</given-names></string-name>, <string-name><surname>Kleinert</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Rac1 governs exercise-stimulated glucose uptake in skeletal muscle through regulation of GLUT4 translocation in mice</article-title>. <source>J Physiol</source>. <year>2016</year>;<volume>594</volume>(<issue>17</issue>):<fpage>4997</fpage>&#x02013;<lpage>5008</lpage>. <comment>Epub 20160616</comment>. doi: <pub-id pub-id-type="doi">10.1113/JP272039</pub-id>
<comment>PubMed PMID: 27061726; PubMed Central PMCID: PMCPMC5009787</comment>.<pub-id pub-id-type="pmid">27061726</pub-id>
</mixed-citation></ref><ref id="cit0083"><label>[83]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bailly</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Degand</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Laine</surname>
<given-names>W</given-names></string-name>, et al</person-group>. <article-title>Implication of Rac1 GTPase in molecular and cellular mitochondrial functions</article-title>. <source>Life Sci</source>. <year>2024</year>;<volume>342</volume>:<fpage>122510</fpage>. <comment>Epub 20240220</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.lfs.2024.122510</pub-id>
<comment>PubMed PMID: 38387701</comment>.<pub-id pub-id-type="pmid">38387701</pub-id>
</mixed-citation></ref><ref id="cit0084"><label>[84]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Daugaard</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Nitsch</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Razaghi</surname>
<given-names>B</given-names></string-name>, et al</person-group>. <article-title>Hace1 controls ROS generation of vertebrate Rac1-dependent NADPH oxidase complexes</article-title>. <source>Nat Commun</source>. <year>2013</year>;<volume>4</volume>(<issue>1</issue>):<fpage>2180</fpage>. doi: <pub-id pub-id-type="doi">10.1038/ncomms3180</pub-id>
<comment>PubMed PMID: 23864022; PubMed Central PMCID: PMCPMC3759041</comment>.<pub-id pub-id-type="pmid">23864022</pub-id>
</mixed-citation></ref><ref id="cit0085"><label>[85]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lee</surname>
<given-names>CF</given-names></string-name>, <string-name><surname>Carley</surname>
<given-names>RE</given-names></string-name>, <string-name><surname>Butler</surname>
<given-names>CA</given-names></string-name>, et al</person-group>. <article-title>Rac GTPase signaling in immune-mediated mechanisms of atherosclerosis</article-title>. <source>Cells</source>. <year>2021</year>;<volume>10</volume>(<issue>11</issue>). <comment>Epub 20211020</comment>. <fpage>2808</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells10112808</pub-id>
<comment>PubMed PMID: 34831028; PubMed Central PMCID: PMCPMC8616135</comment>.<pub-id pub-id-type="pmid">34831028</pub-id>
</mixed-citation></ref><ref id="cit0086"><label>[86]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cannon</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Uribe-Alvarez</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Chernoff</surname>
<given-names>J</given-names></string-name></person-group>. <article-title>RAC1 as a therapeutic target in malignant melanoma</article-title>. <source>Trends Cancer</source>. <year>2020</year>;<volume>6</volume>(<issue>6</issue>):<fpage>478</fpage>&#x02013;<lpage>488</lpage>. <comment>Epub 20200318</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.trecan.2020.02.021</pub-id>
<comment>PubMed PMID: 32460002; PubMed Central PMCID: PMCPMC7380552</comment>.<pub-id pub-id-type="pmid">32460002</pub-id>
</mixed-citation></ref><ref id="cit0087"><label>[87]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Hodis</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Watson</surname>
<given-names>IR</given-names></string-name>, <string-name><surname>Kryukov</surname>
<given-names>GV</given-names></string-name>, et al</person-group>. <article-title>A landscape of driver mutations in melanoma</article-title>. <source>Cell</source>. <year>2012</year>;<volume>150</volume>(<issue>2</issue>):<fpage>251</fpage>&#x02013;<lpage>263</lpage>. <comment>Epub 2012/07/24</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2012.06.024</pub-id>
<comment>PubMed PMID: 22817889; PubMed Central PMCID: PMCPMC3600117</comment>.<pub-id pub-id-type="pmid">22817889</pub-id>
</mixed-citation></ref><ref id="cit0088"><label>[88]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vecchione</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Aretini</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Marino</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>Selective rac-1 inhibition protects from diabetes-induced vascular injury</article-title>. <source>Circ Res</source>. <year>2006</year>;<volume>98</volume>(<issue>2</issue>):<fpage>218</fpage>&#x02013;<lpage>225</lpage>. <comment>Epub 20051215</comment>. doi: <pub-id pub-id-type="doi">10.1161/01.RES.0000200440.18768.30</pub-id>
<comment>PubMed PMID: 16357302</comment>.<pub-id pub-id-type="pmid">16357302</pub-id>
</mixed-citation></ref><ref id="cit0089"><label>[89]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ueda</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Kitazawa</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Ishida</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Crucial role of the small GTPase Rac1 in insulin-stimulated translocation of glucose transporter 4 to the mouse skeletal muscle sarcolemma</article-title>. <source>Faseb J</source>. <year>2010</year>;<volume>24</volume>(<issue>7</issue>):<fpage>2254</fpage>&#x02013;<lpage>2261</lpage>. <comment>Epub 20100304</comment>. doi: <pub-id pub-id-type="doi">10.1096/fj.09-137380</pub-id>
<comment>PubMed PMID: 20203090; PubMed Central PMCID: PMCPMC4183928</comment>.<pub-id pub-id-type="pmid">20203090</pub-id>
</mixed-citation></ref><ref id="cit0090"><label>[90]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Reijnders</surname>
<given-names>MRF</given-names></string-name>, <string-name><surname>Ansor</surname>
<given-names>NM</given-names></string-name>, <string-name><surname>Kousi</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>RAC1 missense mutations in developmental disorders with diverse phenotypes</article-title>. <source>Am J Hum Genet</source>. <year>2017</year>;<volume>101</volume>(<issue>3</issue>):<fpage>466</fpage>&#x02013;<lpage>477</lpage>. <comment>Epub 2017/09/09</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.ajhg.2017.08.007</pub-id>
<comment>PubMed PMID: 28886345; PubMed Central PMCID: PMCPMC5591022</comment>.<pub-id pub-id-type="pmid">28886345</pub-id>
</mixed-citation></ref><ref id="cit0091"><label>[91]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Banka</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Bennington</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Baker</surname>
<given-names>MJ</given-names></string-name>, et al</person-group>. <article-title>Activating RAC1 variants in the switch II region cause a developmental syndrome and alter neuronal morphology</article-title>. <source>Brain</source>. <year>2022</year>;<volume>145</volume>(<issue>12</issue>):<fpage>4232</fpage>&#x02013;<lpage>4245</lpage>. doi: <pub-id pub-id-type="doi">10.1093/brain/awac049</pub-id>
<comment>PubMed PMID: 35139179; PubMed Central PMCID: PMCPMC9762944</comment>.<pub-id pub-id-type="pmid">35139179</pub-id>
</mixed-citation></ref><ref id="cit0092"><label>[92]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sugihara</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Nakatsuji</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Nakamura</surname>
<given-names>K</given-names></string-name>, et al</person-group>. <article-title>Rac1 is required for the formation of three germ layers during gastrulation</article-title>. <source>Oncogene</source>. <year>1998</year>;<volume>17</volume>(<issue>26</issue>):<fpage>3427</fpage>&#x02013;<lpage>3433</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1202595</pub-id>
<comment>PubMed PMID: 10030666</comment>.<pub-id pub-id-type="pmid">10030666</pub-id>
</mixed-citation></ref><ref id="cit0093"><label>[93]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Fernandes</surname>
<given-names>JJ</given-names></string-name>, <string-name><surname>Atreya</surname>
<given-names>KB</given-names></string-name>, <string-name><surname>Desai</surname>
<given-names>KM</given-names></string-name>, et al</person-group>. <article-title>A dominant negative form of Rac1 affects myogenesis of adult thoracic muscles in Drosophila</article-title>. <source>Dev Biol</source>. <year>2005</year>;<volume>285</volume>(<issue>1</issue>):<fpage>11</fpage>&#x02013;<lpage>27</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.ydbio.2005.05.040</pub-id>
<comment>PubMed PMID: 16125691</comment>.<pub-id pub-id-type="pmid">16125691</pub-id>
</mixed-citation></ref><ref id="cit0094"><label>[94]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ridley</surname>
<given-names>AJ</given-names></string-name>, <string-name><surname>Paterson</surname>
<given-names>HF</given-names></string-name>, <string-name><surname>Johnston</surname>
<given-names>CL</given-names></string-name>, et al</person-group>. <article-title>The small GTP-binding protein rac regulates growth factor-induced membrane ruffling</article-title>. <source>Cell</source>. <year>1992</year>;<volume>70</volume>(<issue>3</issue>):<fpage>401</fpage>&#x02013;<lpage>410</lpage>. doi: <pub-id pub-id-type="doi">10.1016/0092-8674(92)90164-8</pub-id>
<comment>PubMed PMID: 1643658</comment>.<pub-id pub-id-type="pmid">1643658</pub-id>
</mixed-citation></ref><ref id="cit0095"><label>[95]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Das</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yin</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>Q</given-names></string-name>, et al</person-group>. <article-title>Single-molecule tracking of small GTPase Rac1 uncovers spatial regulation of membrane translocation and mechanism for polarized signaling</article-title>. <source>Proc Natl Acad Sci U S A</source>. <year>2015</year>;<volume>112</volume>(<issue>3</issue>):<fpage>E267</fpage>&#x02013;<lpage>76</lpage>. <comment>Epub 20150105</comment>. doi: <pub-id pub-id-type="doi">10.1073/pnas.1409667112</pub-id>
<comment>PubMed PMID: 25561548; PubMed Central PMCID: PMCPMC4311845</comment>.<pub-id pub-id-type="pmid">25561548</pub-id>
</mixed-citation></ref><ref id="cit0096"><label>[96]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wong</surname>
<given-names>KW</given-names></string-name>, <string-name><surname>Mohammadi</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Isberg</surname>
<given-names>RR</given-names></string-name></person-group>. <article-title>Disruption of RhoGDI and RhoA regulation by a Rac1 specificity switch mutant</article-title>. <source>J Biol Chem</source>. <year>2006</year>;<volume>281</volume>(<issue>52</issue>):<fpage>40379</fpage>&#x02013;<lpage>40388</lpage>. <comment>Epub 20061029</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M605387200</pub-id>
<comment>PubMed PMID: 17074770</comment>.<pub-id pub-id-type="pmid">17074770</pub-id>
</mixed-citation></ref><ref id="cit0097"><label>[97]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Finkielstein</surname>
<given-names>CV</given-names></string-name>, <string-name><surname>Overduin</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Capelluto</surname>
<given-names>DG</given-names></string-name></person-group>. <article-title>Cell migration and signaling specificity is determined by the phosphatidylserine recognition motif of Rac1</article-title>. <source>J Biol Chem</source>. <year>2006</year>;<volume>281</volume>(<issue>37</issue>):<fpage>27317</fpage>&#x02013;<lpage>27326</lpage>. <comment>Epub 20060721</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M605560200</pub-id>
<comment>PubMed PMID: 16861229</comment>.<pub-id pub-id-type="pmid">16861229</pub-id>
</mixed-citation></ref><ref id="cit0098"><label>[98]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Gurler</surname>
<given-names>SB</given-names></string-name>, <string-name><surname>Novo</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>RAC1B function is essential for breast cancer stem cell maintenance and chemoresistance of breast tumor cells</article-title>. <source>Oncogene</source>. <year>2023</year>;<volume>42</volume>(<issue>9</issue>):<fpage>679</fpage>&#x02013;<lpage>692</lpage>. <comment>Epub 20230105</comment>. doi: <pub-id pub-id-type="doi">10.1038/s41388-022-02574-6</pub-id>
<comment>PubMed PMID: 36599922; PubMed Central PMCID: PMCPMC9957727</comment>.<pub-id pub-id-type="pmid">36599922</pub-id>
</mixed-citation></ref><ref id="cit0099"><label>[99]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Halaban</surname>
<given-names>R</given-names></string-name></person-group>. <article-title>RAC1 and melanoma</article-title>. <source>Clin Ther</source>. <year>2015</year>;<volume>37</volume>(<issue>3</issue>):<fpage>682</fpage>&#x02013;<lpage>685</lpage>. <comment>Epub 20141122</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.clinthera.2014.10.027</pub-id>
<comment>PubMed PMID: 25465943; PubMed Central PMCID: PMCPMC4415501</comment>.<pub-id pub-id-type="pmid">25465943</pub-id>
</mixed-citation></ref><ref id="cit0100"><label>[100]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seiz</surname>
<given-names>JR</given-names></string-name>, <string-name><surname>Klinke</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Scharlibbe</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Different signaling and functionality of Rac1 and Rac1b in the progression of lung adenocarcinoma</article-title>. <source>Biol Chem</source>. <year>2020</year>;<volume>401</volume>(<issue>4</issue>):<fpage>517</fpage>&#x02013;<lpage>531</lpage>. doi: <pub-id pub-id-type="doi">10.1515/hsz-2019-0329</pub-id>
<comment>PubMed PMID: 31811797</comment>.<pub-id pub-id-type="pmid">31811797</pub-id>
</mixed-citation></ref><ref id="cit0101"><label>[101]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zhou</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Licciulli</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Avila</surname>
<given-names>JL</given-names></string-name>, et al</person-group>. <article-title>The Rac1 splice form Rac1b promotes K-ras-induced lung tumorigenesis</article-title>. <source>Oncogene</source>. <year>2013</year>;<volume>32</volume>(<issue>7</issue>):<fpage>903</fpage>&#x02013;<lpage>909</lpage>. <comment>Epub 20120319</comment>. doi: <pub-id pub-id-type="doi">10.1038/onc.2012.99</pub-id>
<comment>PubMed PMID: 22430205; PubMed Central PMCID: PMCPMC3384754</comment>.<pub-id pub-id-type="pmid">22430205</pub-id>
</mixed-citation></ref><ref id="cit0102"><label>[102]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zean Li</surname>
<given-names>JH</given-names></string-name>, <string-name><surname>Du</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Lai</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Targeting the Rac1 pathway for improved prostate cancer therapy using polymeric nanoparticles to deliver of NSC23766</article-title>. <source>Chin Chem Lett</source>. <year>2022</year>;<volume>33</volume>(<issue>5</issue>):<fpage>2496</fpage>&#x02013;<lpage>2500</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cclet.2021.11.078</pub-id></mixed-citation></ref><ref id="cit0103"><label>[103]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Faria</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Capinha</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Simoes-Pereira</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>Extending the Impact of RAC1b Overexpression to follicular thyroid carcinomas</article-title>. <source>Int J Endocrinol</source>. <year>2016</year>;<volume>2016</volume>:<fpage>1972367</fpage>. <comment>Epub 20160405</comment>. doi: <pub-id pub-id-type="doi">10.1155/2016/1972367</pub-id>
<comment>PubMed PMID: 27127508; PubMed Central PMCID: PMCPMC4835645</comment>.<pub-id pub-id-type="pmid">27127508</pub-id>
</mixed-citation></ref><ref id="cit0104"><label>[104]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Silva</surname>
<given-names>AL</given-names></string-name>, <string-name><surname>Carmo</surname>
<given-names>F</given-names></string-name>, <string-name><surname>Bugalho</surname>
<given-names>MJ</given-names></string-name></person-group>. <article-title>RAC1b overexpression in papillary thyroid carcinoma: a role to unravel</article-title>. <source>Eur J Endocrinol</source>. <year>2013</year>;<volume>168</volume>(<issue>6</issue>):<fpage>795</fpage>&#x02013;<lpage>804</lpage>. <comment>Epub 20130429</comment>. doi: <pub-id pub-id-type="doi">10.1530/EJE-12-0960</pub-id>
<comment>PubMed PMID: 23482591</comment>.<pub-id pub-id-type="pmid">23482591</pub-id>
</mixed-citation></ref><ref id="cit0105"><label>[105]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cardama</surname>
<given-names>GA</given-names></string-name>, <string-name><surname>Alonso</surname>
<given-names>DF</given-names></string-name>, <string-name><surname>Gonzalez</surname>
<given-names>N</given-names></string-name>, et al</person-group>. <article-title>Relevance of small GTPase Rac1 pathway in drug and radio-resistance mechanisms: opportunities in cancer therapeutics</article-title>. <source>Crit Rev Oncol Hematol</source>. <year>2018</year>;<volume>124</volume>:<fpage>29</fpage>&#x02013;<lpage>36</lpage>. <comment>Epub 20180204</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.critrevonc.2018.01.012</pub-id>
<comment>PubMed PMID: 29548483</comment>.<pub-id pub-id-type="pmid">29548483</pub-id>
</mixed-citation></ref><ref id="cit0106"><label>[106]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>De</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Rozeboom</surname>
<given-names>BJ</given-names></string-name>, <string-name><surname>Aske</surname>
<given-names>JC</given-names></string-name>, et al</person-group>. <article-title>Active RAC1 promotes tumorigenic phenotypes and therapy resistance in solid tumors</article-title>. <source>Cancers (Basel)</source>. <year>2020</year>;<volume>12</volume>(<issue>6</issue>). <comment>Epub 20200611</comment>. doi: <pub-id pub-id-type="doi">10.3390/cancers12061541</pub-id>
<comment>PubMed PMID: 32545340; PubMed Central PMCID: PMCPMC7352592</comment>.</mixed-citation></ref><ref id="cit0107"><label>[107]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liang</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Oyang</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Rao</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>Rac1, a potential target for tumor therapy</article-title>. <source>Front Oncol</source>. <year>2021</year>;<volume>11</volume>:<fpage>674426</fpage>. <comment>Epub 20210517</comment>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2021.674426</pub-id>
<comment>PubMed PMID: 34079763; PubMed Central PMCID: PMCPMC8165220</comment>.<pub-id pub-id-type="pmid">34079763</pub-id>
</mixed-citation></ref><ref id="cit0108"><label>[108]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lionarons</surname>
<given-names>DA</given-names></string-name>, <string-name><surname>Hancock</surname>
<given-names>DC</given-names></string-name>, <string-name><surname>Rana</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>RAC1(P29S) induces a mesenchymal phenotypic switch via serum response factor to promote melanoma development and therapy resistance</article-title>. <source>Cancer Cell</source>. <year>2019</year>;<volume>36</volume>(<issue>1</issue>):<fpage>68</fpage>&#x02013;<lpage>83 e9</lpage>. <comment>Epub 2019/07/02</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.ccell.2019.05.015</pub-id>
<comment>PubMed PMID: 31257073; PubMed Central PMCID: PMCPMC6617390</comment>.<pub-id pub-id-type="pmid">31257073</pub-id>
</mixed-citation></ref><ref id="cit0109"><label>[109]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Qiu</surname>
<given-names>RG</given-names></string-name>, <string-name><surname>Chen</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Kirn</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>An essential role for rac in Ras transformation</article-title>. <source>Nature</source>. <year>1995</year>;<volume>374</volume>(<issue>6521</issue>):<fpage>457</fpage>&#x02013;<lpage>459</lpage>. doi: <pub-id pub-id-type="doi">10.1038/374457a0</pub-id>
<comment>PubMed PMID: 7700355</comment>.<pub-id pub-id-type="pmid">7700355</pub-id>
</mixed-citation></ref><ref id="cit0110"><label>[110]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tao</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Xu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Fang</surname>
<given-names>Z</given-names></string-name>, et al</person-group>. <article-title>RAC1 as a potential pan-cancer diagnostic, prognostic, and immunological biomarker</article-title>. <source>Transl Cancer Res</source>. <year>2024</year>;<volume>13</volume>(<issue>3</issue>):<fpage>1533</fpage>&#x02013;<lpage>1553</lpage>. <comment>Epub 20240327</comment>. doi: <pub-id pub-id-type="doi">10.21037/tcr-23-2016</pub-id>
<comment>PubMed PMID: 38617518; PubMed Central PMCID: PMCPMC11009796</comment>.<pub-id pub-id-type="pmid">38617518</pub-id>
</mixed-citation></ref><ref id="cit0111"><label>[111]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Lodde</surname>
<given-names>GC</given-names></string-name>, <string-name><surname>Jansen</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Herbst</surname>
<given-names>R</given-names></string-name>, et al</person-group>. <article-title>Characterisation and outcome of RAC1 mutated melanoma</article-title>. <source>Eur J Cancer</source>. <year>2023</year>;<volume>183</volume>:<fpage>1</fpage>&#x02013;<lpage>10</lpage>. <comment>Epub 20230118</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.ejca.2023.01.009</pub-id>
<comment>PubMed PMID: 36773463</comment>.<pub-id pub-id-type="pmid">36773463</pub-id>
</mixed-citation></ref><ref id="cit0112"><label>[112]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Sauzeau</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Beignet</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Vergoten</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>Overexpressed or hyperactivated Rac1 as a target to treat hepatocellular carcinoma</article-title>. <source>Pharmacol Res</source>. <year>2022</year>;<volume>179</volume>:<fpage>106220</fpage>. <comment>Epub 20220409</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.phrs.2022.106220</pub-id>
<comment>PubMed PMID: 35405309</comment>.<pub-id pub-id-type="pmid">35405309</pub-id>
</mixed-citation></ref><ref id="cit0113"><label>[113]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goka</surname>
<given-names>ET</given-names></string-name>, <string-name><surname>Chaturvedi</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Lopez</surname>
<given-names>DTM</given-names></string-name>, et al</person-group>. <article-title>RAC1b overexpression confers resistance to chemotherapy treatment in colorectal cancer</article-title>. <source>Mol Cancer Ther</source>. <year>2019</year>;<volume>18</volume>(<issue>5</issue>):<fpage>957</fpage>&#x02013;<lpage>968</lpage>. <comment>Epub 20190329</comment>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-18-0955</pub-id>
<comment>PubMed PMID: 30926638</comment>.<pub-id pub-id-type="pmid">30926638</pub-id>
</mixed-citation></ref><ref id="cit0114"><label>[114]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Wahoski</surname>
<given-names>CC</given-names></string-name>, <string-name><surname>Singh</surname>
<given-names>B</given-names></string-name></person-group>. <article-title>The roles of RAC1 and RAC1B in colorectal cancer and their potential contribution to cetuximab resistance</article-title>. <source>Cancers (Basel)</source>. <year>2024</year>;<volume>16</volume>(<issue>13</issue>). <comment>Epub 20240706</comment>. <fpage>2472</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cancers16132472</pub-id>
<comment>PubMed PMID: 39001533; PubMed Central PMCID: PMCPMC11240352</comment>.<pub-id pub-id-type="pmid">39001533</pub-id>
</mixed-citation></ref><ref id="cit0115"><label>[115]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Watson</surname>
<given-names>IR</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Cabeceiras</surname>
<given-names>PK</given-names></string-name>, et al</person-group>. <article-title>The RAC1 P29S hotspot mutation in melanoma confers resistance to pharmacological inhibition of RAF</article-title>. <source>Cancer Res</source>. <year>2014</year>;<volume>74</volume>(<issue>17</issue>):<fpage>4845</fpage>&#x02013;<lpage>4852</lpage>. <comment>Epub 20140723</comment>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-14-1232-T</pub-id>
<comment>PubMed PMID: 25056119; PubMed Central PMCID: PMCPMC4167745</comment>.<pub-id pub-id-type="pmid">25056119</pub-id>
</mixed-citation></ref><ref id="cit0116"><label>[116]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Van Allen</surname>
<given-names>EM</given-names></string-name>, <string-name><surname>Wagle</surname>
<given-names>N</given-names></string-name>, <string-name><surname>Sucker</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>The genetic landscape of clinical resistance to RAF inhibition in metastatic melanoma</article-title>. <source>Cancer Discov</source>. <year>2014</year>;<volume>4</volume>(<issue>1</issue>):<fpage>94</fpage>&#x02013;<lpage>109</lpage>. <comment>Epub 20131121</comment>. doi: <pub-id pub-id-type="doi">10.1158/2159-8290.CD-13-0617</pub-id>
<comment>PubMed PMID: 24265153; PubMed Central PMCID: PMCPMC3947264</comment>.<pub-id pub-id-type="pmid">24265153</pub-id>
</mixed-citation></ref><ref id="cit0117"><label>[117]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zeng</surname>
<given-names>RJ</given-names></string-name>, <string-name><surname>Zheng</surname>
<given-names>CW</given-names></string-name>, <string-name><surname>Gu</surname>
<given-names>JE</given-names></string-name>, et al</person-group>. <article-title>RAC1 inhibition reverses cisplatin resistance in esophageal squamous cell carcinoma and induces downregulation of glycolytic enzymes</article-title>. <source>Mol Oncol</source>. <year>2019</year>;<volume>13</volume>(<issue>9</issue>):<fpage>2010</fpage>&#x02013;<lpage>2030</lpage>. <comment>Epub 20190727</comment>. doi: <pub-id pub-id-type="doi">10.1002/1878-0261.12548</pub-id>
<comment>PubMed PMID: 31314174; PubMed Central PMCID: PMCPMC6717762</comment>.<pub-id pub-id-type="pmid">31314174</pub-id>
</mixed-citation></ref><ref id="cit0118"><label>[118]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Tan</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Yi</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>, et al</person-group>. <article-title>RAC1 involves in the radioresistance by mediating epithelial-mesenchymal transition in lung cancer</article-title>. <source>Front Oncol</source>. <year>2020</year>;<volume>10</volume>:<fpage>649</fpage>. <comment>Epub 20200428</comment>. doi: <pub-id pub-id-type="doi">10.3389/fonc.2020.00649</pub-id>
<comment>PubMed PMID: 32411607; PubMed Central PMCID: PMCPMC7198748</comment>.<pub-id pub-id-type="pmid">32411607</pub-id>
</mixed-citation></ref><ref id="cit0119"><label>[119]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Singh</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Karnoub</surname>
<given-names>AE</given-names></string-name>, <string-name><surname>Palmby</surname>
<given-names>TR</given-names></string-name>, et al</person-group>. <article-title>Rac1b, a tumor associated, constitutively active Rac1 splice variant, promotes cellular transformation</article-title>. <source>Oncogene</source>. <year>2004</year>;<volume>23</volume>(<issue>58</issue>):<fpage>9369</fpage>&#x02013;<lpage>9380</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1208182</pub-id>
<comment>PubMed PMID: 15516977</comment>.<pub-id pub-id-type="pmid">15516977</pub-id>
</mixed-citation></ref><ref id="cit0120"><label>[120]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Schwartz</surname>
<given-names>MA</given-names></string-name>, <string-name><surname>Meredith</surname>
<given-names>JE</given-names></string-name>, <string-name><surname>Kiosses</surname>
<given-names>WB</given-names></string-name></person-group>. <article-title>An activated rac mutant functions as a dominant negative for membrane ruffling</article-title>. <source>Oncogene</source>. <year>1998</year>;<volume>17</volume>(<issue>5</issue>):<fpage>625</fpage>&#x02013;<lpage>629</lpage>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1201977</pub-id>
<comment>PubMed PMID: 9704928</comment>.<pub-id pub-id-type="pmid">9704928</pub-id>
</mixed-citation></ref><ref id="cit0121"><label>[121]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matos</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Oliveira</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Velho</surname>
<given-names>S</given-names></string-name>, et al</person-group>. <article-title>B-Raf(V600E) cooperates with alternative spliced Rac1b to sustain colorectal cancer cell survival</article-title>. <source>Gastroenterology</source>. <year>2008</year>;<volume>135</volume>(<issue>3</issue>):<fpage>899</fpage>&#x02013;<lpage>906</lpage>. <comment>Epub 20080522</comment>. doi: <pub-id pub-id-type="doi">10.1053/j.gastro.2008.05.052</pub-id>
<comment>PubMed PMID: 18602919</comment>.<pub-id pub-id-type="pmid">18602919</pub-id>
</mixed-citation></ref><ref id="cit0122"><label>[122]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Melzer</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Hass</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Lehnert</surname>
<given-names>H</given-names></string-name>, et al</person-group>. <article-title>RAC1B: a rho GTPase with versatile functions in malignant transformation and tumor progression</article-title>. <source>Cells</source>. <year>2019</year>;<volume>8</volume>(<issue>1</issue>). <comment>Epub 20190104</comment>. <fpage>21</fpage>. doi: <pub-id pub-id-type="doi">10.3390/cells8010021</pub-id>
<comment>PubMed PMID: 30621237; PubMed Central PMCID: PMCPMC6356296</comment>.<pub-id pub-id-type="pmid">30621237</pub-id>
</mixed-citation></ref><ref id="cit0123"><label>[123]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Beausoleil</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Chauvignac</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Taverne</surname>
<given-names>T</given-names></string-name>, et al</person-group>. <article-title>Structure-activity relationship of isoform selective inhibitors of Rac1/1b GTPase nucleotide binding</article-title>. <source>Bioorg Med Chem Lett</source>. <year>2009</year>;<volume>19</volume>(<issue>19</issue>):<fpage>5594</fpage>&#x02013;<lpage>5598</lpage>. <comment>Epub 20090813</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.bmcl.2009.08.037</pub-id>
<comment>PubMed PMID: 19716293</comment>.<pub-id pub-id-type="pmid">19716293</pub-id>
</mixed-citation></ref><ref id="cit0124"><label>[124]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mehner</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Nassar</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>Tumor cell expression of MMP3 as a prognostic factor for poor survival in pancreatic, pulmonary, and mammary carcinoma</article-title>. <source>Genes Cancer</source>. <year>2015</year>;<volume>6</volume>(<issue>11&#x02013;12</issue>):<fpage>480</fpage>&#x02013;<lpage>489</lpage>. doi: <pub-id pub-id-type="doi">10.18632/genesandcancer.90</pub-id>
<comment>PubMed PMID: 26807201; PubMed Central PMCID: PMCPMC4701227</comment>.<pub-id pub-id-type="pmid">26807201</pub-id>
</mixed-citation></ref><ref id="cit0125"><label>[125]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Li</surname>
<given-names>G</given-names></string-name>, <string-name><surname>Ying</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>H</given-names></string-name>, et al</person-group>. <article-title>Rac1b enhances cell survival through activation of the JNK2/c-JUN/Cyclin-D1 and AKT2/MCL1 pathways</article-title>. <source>Oncotarget</source>. <year>2016</year>;<volume>7</volume>(<issue>14</issue>):<fpage>17970</fpage>&#x02013;<lpage>17985</lpage>. doi: <pub-id pub-id-type="doi">10.18632/oncotarget.7602</pub-id>
<comment>PubMed PMID: 26918455; PubMed Central PMCID: PMCPMC4951264</comment>.<pub-id pub-id-type="pmid">26918455</pub-id>
</mixed-citation></ref><ref id="cit0126"><label>[126]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Liu</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Lee</surname>
<given-names>W</given-names></string-name>, <string-name><surname>Jiang</surname>
<given-names>Z</given-names></string-name>, et al</person-group>. <article-title>Genome and transcriptome sequencing of lung cancers reveal diverse mutational and splicing events</article-title>. <source>Genome Res</source>. <year>2012</year>;<volume>22</volume>(<issue>12</issue>):<fpage>2315</fpage>&#x02013;<lpage>2327</lpage>. <comment>Epub 20121002</comment>. doi: <pub-id pub-id-type="doi">10.1101/gr.140988.112</pub-id>
<comment>PubMed PMID: 23033341; PubMed Central PMCID: PMCPMC3514662</comment>.<pub-id pub-id-type="pmid">23033341</pub-id>
</mixed-citation></ref><ref id="cit0127"><label>[127]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Matos</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Collard</surname>
<given-names>JG</given-names></string-name>, <string-name><surname>Jordan</surname>
<given-names>P</given-names></string-name></person-group>. <article-title>Tumor-related alternatively spliced Rac1b is not regulated by rho-GDP dissociation inhibitors and exhibits selective downstream signaling</article-title>. <source>J Biol Chem</source>. <year>2003</year>;<volume>278</volume>(<issue>50</issue>):<fpage>50442</fpage>&#x02013;<lpage>50448</lpage>. <comment>Epub 20030923</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M308215200</pub-id>
<comment>PubMed PMID: 14506233</comment>.<pub-id pub-id-type="pmid">14506233</pub-id>
</mixed-citation></ref><ref id="cit0128"><label>[128]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Stallings-Mann</surname>
<given-names>ML</given-names></string-name>, <string-name><surname>Waldmann</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Matrix metalloproteinase induction of Rac1b, a key effector of lung cancer progression</article-title>. <source>Sci Transl Med</source>. <year>2012</year>;<volume>4</volume>(<issue>142</issue>):<fpage>142ra95</fpage>. <comment>Epub 2012/07/13</comment>. doi: <pub-id pub-id-type="doi">10.1126/scitranslmed.3004062</pub-id>
<comment>PubMed PMID: 22786680; PubMed Central PMCID: PMCPMC3733503</comment>.</mixed-citation></ref><ref id="cit0129"><label>[129]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Cordaro</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Barreca</surname>
<given-names>MM</given-names></string-name>, <string-name><surname>Zichittella</surname>
<given-names>C</given-names></string-name>, et al</person-group>. <article-title>Regulatory role of lncH19 in RAC1 alternative splicing: implication for RAC1B expression in colorectal cancer</article-title>. <source>J Exp Clin Cancer Res</source>. <year>2024</year>;<volume>43</volume>(<issue>1</issue>):<fpage>217</fpage>. <comment>Epub 20240805</comment>. doi: <pub-id pub-id-type="doi">10.1186/s13046-024-03139-z</pub-id>
<comment>PubMed PMID: 39098911; PubMed Central PMCID: PMCPMC11299361</comment>.<pub-id pub-id-type="pmid">39098911</pub-id>
</mixed-citation></ref><ref id="cit0130"><label>[130]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Pethe</surname>
<given-names>VV</given-names></string-name>, <string-name><surname>Charames</surname>
<given-names>GS</given-names></string-name>, <string-name><surname>Bapat</surname>
<given-names>B</given-names></string-name></person-group>. <article-title>Rac1b recruits dishevelled and beta-catenin to wnt target gene promoters independent of Wnt3A stimulation</article-title>. <source>Int J Oncol</source>. <year>2011</year>;<volume>39</volume>(<issue>4</issue>):<fpage>805</fpage>&#x02013;<lpage>810</lpage>. <comment>Epub 20110606</comment>. doi: <pub-id pub-id-type="doi">10.3892/ijo.2011.1066</pub-id>
<comment>PubMed PMID: 21667018</comment>.<pub-id pub-id-type="pmid">21667018</pub-id>
</mixed-citation></ref><ref id="cit0131"><label>[131]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Goka</surname>
<given-names>ET</given-names></string-name>, <string-name><surname>Lippman</surname>
<given-names>ME</given-names></string-name></person-group>. <article-title>Loss of the E3 ubiquitin ligase HACE1 results in enhanced Rac1 signaling contributing to breast cancer progression</article-title>. <source>Oncogene</source>. <year>2015</year>;<volume>34</volume>(<issue>42</issue>):<fpage>5395</fpage>&#x02013;<lpage>5405</lpage>. <comment>Epub 20150209</comment>. doi: <pub-id pub-id-type="doi">10.1038/onc.2014.468</pub-id>
<comment>PubMed PMID: 25659579; PubMed Central PMCID: PMCPMC4633721</comment>.<pub-id pub-id-type="pmid">25659579</pub-id>
</mixed-citation></ref><ref id="cit0132"><label>[132]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Torrino</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Visvikis</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Doye</surname>
<given-names>A</given-names></string-name>, et al</person-group>. <article-title>The E3 ubiquitin-ligase HACE1 catalyzes the ubiquitylation of active Rac1</article-title>. <source>Dev Cell</source>. <year>2011</year>;<volume>21</volume>(<issue>5</issue>):<fpage>959</fpage>&#x02013;<lpage>965</lpage>. <comment>Epub 20111027</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.devcel.2011.08.015</pub-id>
<comment>PubMed PMID: 22036506</comment>.<pub-id pub-id-type="pmid">22036506</pub-id>
</mixed-citation></ref><ref id="cit0133"><label>[133]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mettouchi</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Lemichez</surname>
<given-names>E</given-names></string-name></person-group>. <article-title>Ubiquitylation of active Rac1 by the E3 ubiquitin-ligase HACE1</article-title>. <source>Small GTPases</source>. <year>2012</year>;<volume>3</volume>(<issue>2</issue>):<fpage>102</fpage>&#x02013;<lpage>106</lpage>. doi: <pub-id pub-id-type="doi">10.4161/sgtp.19221</pub-id>
<comment>PubMed PMID: 22790197; PubMed Central PMCID: PMCPMC3408975</comment>.<pub-id pub-id-type="pmid">22790197</pub-id>
</mixed-citation></ref><ref id="cit0134"><label>[134]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Visvikis</surname>
<given-names>O</given-names></string-name>, <string-name><surname>Lores</surname>
<given-names>P</given-names></string-name>, <string-name><surname>Boyer</surname>
<given-names>L</given-names></string-name>, et al</person-group>. <article-title>Activated Rac1, but not the tumorigenic variant Rac1b, is ubiquitinated on lys 147 through a JNK-regulated process</article-title>. <source>FEBS J</source>. <year>2008</year>;<volume>275</volume>(<issue>2</issue>):<fpage>386</fpage>&#x02013;<lpage>396</lpage>. <comment>Epub 20071217</comment>. doi: <pub-id pub-id-type="doi">10.1111/j.1742-4658.2007.06209.x</pub-id>
<comment>PubMed PMID: 18093184</comment>.<pub-id pub-id-type="pmid">18093184</pub-id>
</mixed-citation></ref><ref id="cit0135"><label>[135]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Mehner</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Miller</surname>
<given-names>E</given-names></string-name>, <string-name><surname>Khauv</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Tumor cell-derived MMP3 orchestrates Rac1b and tissue alterations that promote pancreatic adenocarcinoma</article-title>. <source>Mol Cancer Res</source>. <year>2014</year>;<volume>12</volume>(<issue>10</issue>):<fpage>1430</fpage>&#x02013;<lpage>1439</lpage>. <comment>Epub 20140521</comment>. doi: <pub-id pub-id-type="doi">10.1158/1541-7786.MCR-13-0557-T</pub-id>
<comment>PubMed PMID: 24850902; PubMed Central PMCID: PMCPMC4201965</comment>.<pub-id pub-id-type="pmid">24850902</pub-id>
</mixed-citation></ref><ref id="cit0136"><label>[136]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Uribe-Alvarez</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Guerrero-Rodriguez</surname>
<given-names>SL</given-names></string-name>, <string-name><surname>Rhodes</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>Targeting effector pathways in RAC1 P29S -driven malignant melanoma</article-title>. <source>Small GTPases</source>. <year>2021</year>;<volume>2020</volume>(<issue>4</issue>):<fpage>1</fpage>&#x02013;<lpage>9</lpage>. <comment>Epub 2020/02/12</comment>. doi: <pub-id pub-id-type="doi">10.1080/21541248.2020.1728469</pub-id>
<comment>PubMed PMID: 32043900</comment>.</mixed-citation></ref><ref id="cit0137"><label>[137]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Araiza-Olivera</surname>
<given-names>D</given-names></string-name>, <string-name><surname>Feng</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Semenova</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>Suppression of RAC1-driven malignant melanoma by group a PAK inhibitors</article-title>. <source>Oncogene</source>. <year>2018</year>;<volume>37</volume>(<issue>7</issue>):<fpage>944</fpage>&#x02013;<lpage>952</lpage>. <comment>Epub 2017/10/24</comment>. doi: <pub-id pub-id-type="doi">10.1038/onc.2017.400</pub-id>
<comment>PubMed PMID: 29059171; PubMed Central PMCID: PMCPMC5814328</comment>.<pub-id pub-id-type="pmid">29059171</pub-id>
</mixed-citation></ref><ref id="cit0138"><label>[138]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Philpott</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Tovell</surname>
<given-names>H</given-names></string-name>, <string-name><surname>Frayling</surname>
<given-names>IM</given-names></string-name>, et al</person-group>. <article-title>The NF1 somatic mutational landscape in sporadic human cancers</article-title>. <source>Hum Genomics</source>. <year>2017</year>;<volume>11</volume>(<issue>1</issue>):<fpage>13</fpage>. <comment>Epub 20170621</comment>. doi: <pub-id pub-id-type="doi">10.1186/s40246-017-0109-3</pub-id>
<comment>PubMed PMID: 28637487; PubMed Central PMCID: PMCPMC5480124</comment>.<pub-id pub-id-type="pmid">28637487</pub-id>
</mixed-citation></ref><ref id="cit0139"><label>[139]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Vu</surname>
<given-names>HL</given-names></string-name>, <string-name><surname>Rosenbaum</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Purwin</surname>
<given-names>TJ</given-names></string-name>, et al</person-group>. <article-title>RAC1 P29S regulates PD-L1 expression in melanoma</article-title>. <source>Pigment Cell Melanoma Res</source>. <year>2015</year>;<volume>28</volume>(<issue>5</issue>):<fpage>590</fpage>&#x02013;<lpage>598</lpage>. doi: <pub-id pub-id-type="doi">10.1111/pcmr.12392</pub-id>
<comment>PubMed PMID: 26176707; PubMed Central PMCID: PMCPMC4675336</comment>.<pub-id pub-id-type="pmid">26176707</pub-id>
</mixed-citation></ref><ref id="cit0140"><label>[140]</label><mixed-citation publication-type="book"><person-group person-group-type="author"><string-name><surname>Cannon</surname>
<given-names>AC</given-names></string-name>, <string-name><surname>Budagyan</surname>
<given-names>K</given-names></string-name>, <string-name><surname>Uribe-Alvarez</surname>
<given-names>C</given-names></string-name>, et al</person-group>. <source>Unique vulnerability of RAC1-mutant melanoma to combined inhibition of CDK9 and immune checkpoints. bioRxiv. 2023</source>. <comment>Epub 20230628</comment>. doi: <pub-id pub-id-type="doi">10.1101/2023.06.27.546707</pub-id>
<comment>PubMed PMID: 37425776; PubMed Central PMCID: PMCPMC10327161</comment>.</mixed-citation></ref><ref id="cit0141"><label>[141]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Strub</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Ballotti</surname>
<given-names>R</given-names></string-name>, <string-name><surname>Bertolotto</surname>
<given-names>C</given-names></string-name></person-group>. <article-title>The &#x0201c;ART&#x0201d; of Epigenetics in melanoma: from histone &#x0201c;alterations, to resistance and therapies&#x0201d;</article-title>. <source>Theranostics</source>. <year>2020</year>;<volume>10</volume>(<issue>4</issue>):<fpage>1777</fpage>&#x02013;<lpage>1797</lpage>. doi: <pub-id pub-id-type="doi">10.7150/thno.36218</pub-id><pub-id pub-id-type="pmid">32042336</pub-id>
</mixed-citation></ref><ref id="cit0142"><label>[142]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Seng</surname>
<given-names>TJ</given-names></string-name>, <string-name><surname>Low</surname>
<given-names>JS</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>H</given-names></string-name>, et al</person-group>. <article-title>The major 8p22 tumor suppressor DLC1 is frequently silenced by methylation in both endemic and sporadic nasopharyngeal, esophageal, and cervical carcinomas, and inhibits tumor cell colony formation</article-title>. <source>Oncogene</source>. <year>2007</year>;<volume>26</volume>(<issue>6</issue>):<fpage>934</fpage>&#x02013;<lpage>944</lpage>. <comment>Epub 20060724</comment>. doi: <pub-id pub-id-type="doi">10.1038/sj.onc.1209839</pub-id>
<comment>PubMed PMID: 16862168</comment>.<pub-id pub-id-type="pmid">16862168</pub-id>
</mixed-citation></ref><ref id="cit0143"><label>[143]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Jones</surname>
<given-names>PA</given-names></string-name>, <string-name><surname>Baylin</surname>
<given-names>SB</given-names></string-name></person-group>. <article-title>The fundamental role of epigenetic events in cancer</article-title>. <source>Nat Rev Genet</source>. <year>2002</year>;<volume>3</volume>(<issue>6</issue>):<fpage>415</fpage>&#x02013;<lpage>428</lpage>. doi: <pub-id pub-id-type="doi">10.1038/nrg816</pub-id>
<comment>PubMed PMID: 12042769</comment>.<pub-id pub-id-type="pmid">12042769</pub-id>
</mixed-citation></ref><ref id="cit0144"><label>[144]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bhat</surname>
<given-names>AV</given-names></string-name>, <string-name><surname>Palanichamy Kala</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Rao</surname>
<given-names>VK</given-names></string-name>, et al</person-group>. <article-title>Epigenetic regulation of the PTEN-AKT-RAC1 Axis by G9a is critical for tumor growth in alveolar Rhabdomyosarcoma</article-title>. <source>Cancer Res</source>. <year>2019</year>;<volume>79</volume>(<issue>9</issue>):<fpage>2232</fpage>&#x02013;<lpage>2243</lpage>. <comment>Epub 20190304</comment>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-18-2676</pub-id>
<comment>PubMed PMID: 30833420</comment>.<pub-id pub-id-type="pmid">30833420</pub-id>
</mixed-citation></ref><ref id="cit0145"><label>[145]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Golden</surname>
<given-names>SA</given-names></string-name>, <string-name><surname>Christoffel</surname>
<given-names>DJ</given-names></string-name>, <string-name><surname>Heshmati</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Epigenetic regulation of RAC1 induces synaptic remodeling in stress disorders and depression</article-title>. <source>Nat Med</source>. <year>2013</year>;<volume>19</volume>(<issue>3</issue>):<fpage>337</fpage>&#x02013;<lpage>344</lpage>. <comment>Epub 20130217</comment>. doi: <pub-id pub-id-type="doi">10.1038/nm.3090</pub-id>
<comment>PubMed PMID: 23416703; PubMed Central PMCID: PMCPMC3594624</comment>.<pub-id pub-id-type="pmid">23416703</pub-id>
</mixed-citation></ref><ref id="cit0146"><label>[146]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yuan</surname>
<given-names>M</given-names></string-name>, <string-name><surname>Yang</surname>
<given-names>B</given-names></string-name>, <string-name><surname>Rothschild</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>Epigenetic regulation in major depression and other stress-related disorders: molecular mechanisms, clinical relevance and therapeutic potential</article-title>. <source>Signal Transduct Target Ther</source>. <year>2023</year>;<volume>8</volume>(<issue>1</issue>):<fpage>309</fpage>. <comment>Epub 20230830</comment>. doi: <pub-id pub-id-type="doi">10.1038/s41392-023-01519-z</pub-id>
<comment>PubMed PMID: 37644009; PubMed Central PMCID: PMCPMC10465587</comment>.<pub-id pub-id-type="pmid">37644009</pub-id>
</mixed-citation></ref><ref id="cit0147"><label>[147]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Chen</surname>
<given-names>MW</given-names></string-name>, <string-name><surname>Hua</surname>
<given-names>KT</given-names></string-name>, <string-name><surname>Kao</surname>
<given-names>HJ</given-names></string-name>, et al</person-group>. <article-title>H3K9&#x000a0;histone methyltransferase G9a promotes lung cancer invasion and metastasis by silencing the cell adhesion molecule ep-CAM</article-title>. <source>Cancer Res</source>. <year>2010</year>;<volume>70</volume>(<issue>20</issue>):<fpage>7830</fpage>&#x02013;<lpage>7840</lpage>. <comment>Epub 20101012</comment>. doi: <pub-id pub-id-type="doi">10.1158/0008-5472.CAN-10-0833</pub-id>
<comment>PubMed PMID: 20940408</comment>.<pub-id pub-id-type="pmid">20940408</pub-id>
</mixed-citation></ref><ref id="cit0148"><label>[148]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Ding</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Li</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Wang</surname>
<given-names>X</given-names></string-name>, et al</person-group>. <article-title>The histone H3 methyltransferase G9A epigenetically activates the serine-glycine synthesis pathway to sustain cancer cell survival and proliferation</article-title>. <source>Cell Metab</source>. <year>2013</year>;<volume>18</volume>(<issue>6</issue>):<fpage>896</fpage>&#x02013;<lpage>907</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.cmet.2013.11.004</pub-id>
<comment>PubMed PMID: 24315373; PubMed Central PMCID: PMCPMC3878056</comment>.<pub-id pub-id-type="pmid">24315373</pub-id>
</mixed-citation></ref><ref id="cit0149"><label>[149]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dong</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Yao</surname>
<given-names>J</given-names></string-name>, et al</person-group>. <article-title>G9a interacts with Snail and is critical for Snail-mediated E-cadherin repression in human breast cancer</article-title>. <source>J Clin Invest</source>. <year>2012</year>;<volume>122</volume>(<issue>4</issue>):<fpage>1469</fpage>&#x02013;<lpage>1486</lpage>. <comment>Epub 20120312</comment>. doi: <pub-id pub-id-type="doi">10.1172/JCI57349</pub-id>
<comment>PubMed PMID: 22406531; PubMed Central PMCID: PMCPMC3314447</comment>.<pub-id pub-id-type="pmid">22406531</pub-id>
</mixed-citation></ref><ref id="cit0150"><label>[150]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Bailly</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Beignet</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Loirand</surname>
<given-names>G</given-names></string-name>, et al</person-group>. <article-title>Rac1 as a therapeutic anticancer target: promises and limitations</article-title>. <source>Biochem Pharmacol</source>. <year>2022</year>;<volume>203</volume>:<fpage>115180</fpage>. <comment>Epub 20220716</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.bcp.2022.115180</pub-id>
<comment>PubMed PMID: 35853497</comment>.<pub-id pub-id-type="pmid">35853497</pub-id>
</mixed-citation></ref><ref id="cit0151"><label>[151]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Surviladze</surname>
<given-names>Z</given-names></string-name>, <string-name><surname>Waller</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>Y</given-names></string-name>, et al</person-group>. <article-title>Identification of a small GTPase inhibitor using a high-throughput flow cytometry bead-based multiplex assay</article-title>. <source>J Biomol Screen</source>. <year>2010</year>;<volume>15</volume>(<issue>1</issue>):<fpage>10</fpage>&#x02013;<lpage>20</lpage>. <comment>Epub 20091211</comment>. doi: <pub-id pub-id-type="doi">10.1177/1087057109352240</pub-id>
<comment>PubMed PMID: 20008126; PubMed Central PMCID: PMCPMC3433230</comment>.<pub-id pub-id-type="pmid">20008126</pub-id>
</mixed-citation></ref><ref id="cit0152"><label>[152]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Shutes</surname>
<given-names>A</given-names></string-name>, <string-name><surname>Onesto</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Picard</surname>
<given-names>V</given-names></string-name>, et al</person-group>. <article-title>Specificity and mechanism of action of EHT 1864, a novel small molecule inhibitor of rac family small GTPases</article-title>. <source>J Biol Chem</source>. <year>2007</year>;<volume>282</volume>(<issue>49</issue>):<fpage>35666</fpage>&#x02013;<lpage>35678</lpage>. <comment>Epub 20071011</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M703571200</pub-id>
<comment>PubMed PMID: 17932039</comment>.<pub-id pub-id-type="pmid">17932039</pub-id>
</mixed-citation></ref><ref id="cit0153"><label>[153]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Montalvo-Ortiz</surname>
<given-names>BL</given-names></string-name>, <string-name><surname>Castillo-Pichardo</surname>
<given-names>L</given-names></string-name>, <string-name><surname>Hernandez</surname>
<given-names>E</given-names></string-name>, et al</person-group>. <article-title>Characterization of EHop-016, novel small molecule inhibitor of rac GTPase</article-title>. <source>J Biol Chem</source>. <year>2012</year>;<volume>287</volume>(<issue>16</issue>):<fpage>13228</fpage>&#x02013;<lpage>13238</lpage>. <comment>Epub 20120301</comment>. doi: <pub-id pub-id-type="doi">10.1074/jbc.M111.334524</pub-id>
<comment>PubMed PMID: 22383527; PubMed Central PMCID: PMCPMC3339933</comment>.<pub-id pub-id-type="pmid">22383527</pub-id>
</mixed-citation></ref><ref id="cit0154"><label>[154]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Zheng</surname>
<given-names>C</given-names></string-name>, <string-name><surname>Wu</surname>
<given-names>X</given-names></string-name>, <string-name><surname>Zeng</surname>
<given-names>R</given-names></string-name>, et al</person-group>. <article-title>Computational prediction of hot spots and binding site of inhibitor NSC23766 on Rac1 binding with Tiam1</article-title>. <source>Front Chem</source>. <year>2020</year>;<volume>8</volume>:<fpage>625437</fpage>. <comment>Epub 20210202</comment>. doi: <pub-id pub-id-type="doi">10.3389/fchem.2020.625437</pub-id>
<comment>PubMed PMID: 33604328; PubMed Central PMCID: PMCPMC7884829</comment>.<pub-id pub-id-type="pmid">33604328</pub-id>
</mixed-citation></ref><ref id="cit0155"><label>[155]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Yoshida</surname>
<given-names>T</given-names></string-name>, <string-name><surname>Zhang</surname>
<given-names>Y</given-names></string-name>, <string-name><surname>Rivera Rosado</surname>
<given-names>LA</given-names></string-name>, et al</person-group>. <article-title>Blockade of Rac1 activity induces G1 cell cycle arrest or apoptosis in breast cancer cells through downregulation of cyclin D1, survivin, and X-linked inhibitor of apoptosis protein</article-title>. <source>Mol Cancer Ther</source>. <year>2010</year>;<volume>9</volume>(<issue>6</issue>):<fpage>1657</fpage>&#x02013;<lpage>1668</lpage>. <comment>Epub 20100601</comment>. doi: <pub-id pub-id-type="doi">10.1158/1535-7163.MCT-09-0906</pub-id>
<comment>PubMed PMID: 20515940</comment>.<pub-id pub-id-type="pmid">20515940</pub-id>
</mixed-citation></ref><ref id="cit0156"><label>[156]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Dutting</surname>
<given-names>S</given-names></string-name>, <string-name><surname>Heidenreich</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Cherpokova</surname>
<given-names>D</given-names></string-name>, et al</person-group>. <article-title>Critical off-target effects of the widely used Rac1 inhibitors NSC23766 and EHT1864 in mouse platelets</article-title>. <source>J Thromb Haemost</source>. <year>2015</year>;<volume>13</volume>(<issue>5</issue>):<fpage>827</fpage>&#x02013;<lpage>838</lpage>. <comment>Epub 20150223</comment>. doi: <pub-id pub-id-type="doi">10.1111/jth.12861</pub-id>
<comment>PubMed PMID: 25628054</comment>.<pub-id pub-id-type="pmid">25628054</pub-id>
</mixed-citation></ref><ref id="cit0157"><label>[157]</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name><surname>Morstein</surname>
<given-names>J</given-names></string-name>, <string-name><surname>Bowcut</surname>
<given-names>V</given-names></string-name>, <string-name><surname>Fernando</surname>
<given-names>M</given-names></string-name>, et al</person-group>. <article-title>Targeting ras-, rho-, and rab-family GTPases via a conserved cryptic pocket</article-title>. <source>Cell</source>. <year>2024</year>;<volume>187</volume>(<issue>22</issue>):<fpage>6379</fpage>&#x02013;<lpage>92 e17</lpage>. <comment>Epub 20240909</comment>. doi: <pub-id pub-id-type="doi">10.1016/j.cell.2024.08.017</pub-id>
<comment>PubMed PMID: 39255801; PubMed Central PMCID: PMCPMC11531380</comment>.<pub-id pub-id-type="pmid">39255801</pub-id>
</mixed-citation></ref></ref-list></back></article>